## University of California, San Francisco CURRICULUM VITAE

Name: Bernard J Guglielmo, PharmD

Position: Professor of Clinical Pharmacy, Step 9 Clinical Pharmacy School of Pharmacy

Address: Box 0622, 521 Parnassus Ave, Clinic Sci, 156 University of California, San Francisco San Francisco, CA 94143 Voice: 415 476-8010 Fax: 415 476-6632 email: guglielmoj@pharmacy.ucsf.edu

## EDUCATION

1969 - 1973	University of Santa Clara	B.S.	Biology
1974 - 1978	University of Southern California	Pharm.D.	Pharmacy
1978 - 1979	University of California, San Francisco	Residency	Pharmacy

#### LICENSES, CERTIFICATION

1978 Licentiate in Pharmacy, California

#### PRINCIPAL POSITIONS HELD

2012 -	University of California San Francisco	Interim Dean	School of Pharmacy
2006 - 2012	University of California, San Francisco	Chairman	Department of Clinical Pharmacy
2007 - 2007	University of California, San Francisco	Interim director	Department of Pharmaceutical Services
2007 - 2012	University of California, San Francisco	Associate Director	Department of Pharmaceutical Services

#### OTHER POSITIONS HELD CONCURRENTLY

2006 - 2012	Medication Outcomes Center	Director	Department of Clinical

## HONORS AND AWARDS

1981	Long Foundation Award for Excellence in Teaching	UCSF
1981	Pharmacy Residents Preceptorship Award	UCSF
1985	Pharmacy Residents Preceptorship Award	UCSF
1986	Long Foundation Award for Excellence in Teaching, Pharmacy Class of 1986	UCSF
1987	Pharmacy Residents Preceptorship Award	UCSF
1988	Pharmacy Residents Preceptorship Award	UCSF
1989	Pharmacy Residents Preceptorship Award	UCSF
1992	Academic Senate Distinction in Teaching Award	UCSF
1992	Commencement Speaker, Class of 1992, School of Pharmacy	UCSF
1993	Fellow	CSHP
1995	Pharmacy Leadership Society Recognition	Phi Lambda Sigma
1995	Pharmacy Residents Preceptorship Award	UCSF
1999	Long Prize for Excellence in Teaching	UCSF
2005	Vincent G. Pons Award in Clinical Infectious Diseases	UCSF
2006	Deans Award for Teaching Excellence	UCSF
2007	Deans Award for Teaching Excellence	UCSF
2007	Nominee, Faculty Mentoring Program Lifetime Achievement in Mentoring Award	UCSF
2008	Nominee, Faculty Mentoring Program Lifetime Achievement in Mentoring Award	UCSF
2008	Deans Award for Teaching Excellence	UCSF
2009	Nominee, Faculty Mentoring Program Lifetime Achievement in Mentoring Award	UCSF
2010	Recipient Faculty Mentoring Program Lifetime Achievement in Mentoring Award	UCSF
2011	Deans Apples for Preceptor Award	UCSF
2011	Fellow American College Clinical Pharmacy	ACCP

## **KEYWORDS/AREAS OF INTEREST**

Infectious diseases, antimicrobial usage, evidence-based medicine

# **PROFESSIONAL ACTIVITIES**

## CLINICAL

Infectious diseases pharmacist at UCSF Medical Center

## SUMMARY OF CLINICAL ACTIVITIES

Oversight of antimicrobial stewardship at UCSF Medical Center, including Children's Hospital, Mt Zion. Consultant to adult and pediatric infectious diseases services. Development of guidelines toward the safe, effective use of antimicrobials. Participation in the Infectious Diseases Management Program.

## **PROFESSIONAL ORGANIZATIONS**

#### <u>Memberships</u>

- American Society of Health Systems Pharmacists
- California Society of Health Systems Pharmacists
- American Association of Colleges of Pharmacy
- American Society of Microbiology
- American College of Clinical Pharmacy
- Society of Infectious Diseases Pharmacists
- American Association for the Advancement of Science
- Alliance for the Prudent Use of Antibiotics
- Infectious Diseases Society of America

#### Service to Professional Organizations

1981 - 1982	Northern California Society of Hospital Pharmacists	President-Elect
1982 - 1983	Northern California Society of Hospital Pharmacists Delegate, California Society of Hospital Pharmacists	President
1983 - 1983	California Society of Hospital Pharmacists	Council on Organizational Affairs
1983 - 1983	Northern California Society of Hospital Pharmacists	Immediate Past President
1983 - 1983	Critical Care Residency, American Society of Hospital Pharmacists	Advisory Working Group
1983 - 1984	Seminar '84, California Society of Hospital Pharmacists	Continuing Education Committee
1984 - 1984	Council on Clinical Affairs, California Society of Hospital Pharmacists	Chairman
1985 - 1985	California Society of Hospital Pharmacists	Secretary

1986 - 1987	California Society of Hospital Pharmacists	Board of Directors
1987 - 1987	Western Regional Conference on Clinical Pharmacy Practice	Invited Attendee
1988 - 1988	ASHP House of Delegates	CSHP Representative
1989 - 1989	ASHP House of Delegates	Alternate CSHP Representative
1989 - 1989	ASHP on Prophylactic Antibiotics in Surgery	Ad Hoc Committee
1989 - 1989	ASHP for 1989 Midyear Clinical Meeting	Educational Programming Associate
1989 - 1990	ACCP	Membership Committee
1990 - 1990	ASHP House of Delegates	CSHP Representative
1990 - 1991	ASHP	Educational Programming Associate
1991 - 1991	ASHP House of Delegates	CSHP Representative
1991 - 1991	Specialty Interest Session, ASHP Annual	Moderator
1992 - 1992	ASHP House of Delegates	CSHP Alternate Representative
1993 - 1993	University Hospital Consortium TAC on Colony Stimulating Factors	Expert Panel
1995 - 1999	ASHP for Guidelines on Surgical and Nonsurgical Prophylaxis	Expert Panel
1995 - 1999	Society of Infectious Diseases Pharmacists	Ad Hoc Committee on Outcomes Research
1995 - 1995	University Hospital Consortium: RSV Immune Globulin	Expert Reviewer
1998 - 1998	University Hospital Consortium: Growth Hormone for AIDS Wasting	Expert Reviewer
1999 - 1999	California Society of Hospital Pharmacists	Council on Educational Affairs
2000 - 2000	Society of Infectious Diseases	Pharmacists Program Committee
2001 - 2001	UCSF Institute for Health Policy Community- Acquired Pneumonia	Clinical Advisory Panel
2002 - 2002	Centers for Disease Control and Prevention, Hospital Infections Program (HIP)	Working Group on Antibiotic Cycling
2002 - 2002	Joint Commission on Accreditation of Hospitals Organization (JCAHO) Community-Acquired Pneumonia	Clinical Advisory Panel
2002 - 2002	Masters in Clinical Pharmacy at The Chinese University of Hong Kong	External Reviewer

2003 - 2003	NIH Office of AIDS Research on Natural History and Epidemiology Research	Planning Group
2005 - 2006	American Association Colleges of Pharmacy (AACP)	Council on Educational Affairs
2008 - 2008	American College Clinical Pharmacy (ACCP) Annual Meeting Department Chairs Meeting	Chair
2009 - 2010	American Association Colleges of Pharmacy (AACP) Faculty Affairs Committee	Chair
2009 - 2011	American College Clinical Pharmacy (ACCP)	Nominations Committee
2010 - 2010	American College Clinical Pharmacy Best Research Award	Chair
2010 - 2011	American Association Colleges of Pharmacy Council of Faculties Rules and Regulations Committee	Chair
2011 - 2013	American College of Clinical Pharmacy Nominations Committee	Chair
2011 - 2011	American College Clinical Pharmacy (ACCP) Annual Meeting Best Paper Judging	Chair
2011 - 2011	American College Clinical Pharmacy (ACCP) Clinical Faculty Survival Guide	Reviewer
2012 - 2012	Infectious Diseases American College Clinical Pharmacy (ACCP) 2012 Mock Exam	Item Writer

#### SERVICE TO PROFESSIONAL PUBLICATIONS

- 1979 2011 Referee, American Journal of Health Systems Pharmacists
- 1979 2012 Referee, Annals of Pharmacotherapy
- 1982 1982 Referee, Contemporary Pharmacy Practice
- 1983 2006 Referee, American Society of Health Systems Pharmacists Annual Meeting
- 1983 2006 Referee, American Society of Health Systems Pharmacists Midyear Clinical Meeting
- 1987 1995 Referee, Clinical Pharmacy
- 1988 1990 Referee, American Hospital Formulary Service
- 1989 1989 Referee, Medical Letter
- 1989 1989 Referee, Western Journal of Medicine
- 1990 2012 Referee, American College of Clinical Pharmacy, Annual Meeting
- 1991 1991 Referee, Clinical Pharmacokinetics
- 1992 1992 Referee, PharmacoEconomics
- 1994 1994 Referee, Journal of Infectious Diseases
- 1994 1994 Expert Reviewer, Pharmacotherapy Self-Assessment Program, American

College of Clinical Pharmacy

- 1994 2000 Referee, Hospital Pharmacy
- 1995 Advisory Board, Pharmacist's Letter
- 1995 1995 Expert Reviewer, Pharmacotherapy Self-Assessment Program, American College of Clinical Pharmacy
- 1997 1997 Referee, CNS Drugs
- 1998 Referee, Clinical Infectious Diseases
- 1998 2005 Referee, American Journal of Medicine
- 1998 1998 Referee, Discern Insight
- 1998 2012 Various radio and television interviews
- 1999 Research and Review Editorial Staff, Prescribers Letter
- 2002 Referee, Journal of General Internal Medicine
- 2003 2012 Referee, JAMA
- 2003 Editorial Board, Annals of Pharmacotherapy
- 2003 2003 Reviewer, Natural Medicines in Clinical Management of Colds and Flu
- 2004 2004 Advisor, Mosby's 2005 Nurse's Drug Consult
- 2004 2011 Referee, Pharmacotherapy
- 2005 2011 Referee, Journal of Biomedicine and Biotechnology
- 2005 2011 Referee, BioMedCentral Infectious Diseases
- 2006 Referee, Archives of Internal Medicine
- 2007 2011 Referee, American Journal Infection Control
- 2007 2007 Referee, Epidemiology and Infection
- 2007 2007 Referee, American Journal of Critical Care
- 2008 2012 Referee, Expert Opinion Infectious Diseases
- 2009 Referee, Journal Antimicrobial Chemotherapy
- 2010 Referee, Journal Hospital Medicine
- 2010 2010 Expert Reviewer, Pharmacotherapy Self-Assessment Program, American College of Clinical Pharmacy
- 2010 Editorial Board AHRQ WebM&M
- 2011 2012 newMentor Infectious Diseases Order Sets and Comparative Literature Review
- 2012 Referee, Currents in Pharmacy Teaching and Learning
- 2012 Medical Advisory Board, Consumers Reports

#### INVITED PRESENTATIONS

#### INTERNATIONAL

1991 Treatment of Infection in the Immunocompromised

Patient. Pan Pacific VI. Honolulu, Hawaii (May)

- 1994 Practical Strategies for the Appropriate Use of Antimicrobials. National Congress on Hospital Pharmacy. Utrecht, Netherlands (June)
- 1997 Antibiotic Formulary Control Strategies. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (September)
- 2002 Rational Antibacterial Use and the Risk of Resistance. Pharmaceutical Society of Hong Kong. Hong Kong (December)
- 2003 Drug Treatment of Prion Disease: Applicable Pharmacokinetics of Quinacrine. 16th Annual Major Issues in Prion Research, San Francisco
- 2004 Challenges Associated with the Interpretation of Quinacrine Concentrations in Brain Tissue. 17th Annual Major Issues in Prion Research, San Francisco (May)
- 2004 Development and Evaluation of Antimicrobial Intervention Programs: A Practical Approach. Canadian Society of Hospital Pharmacists 36th Annual Professional Practice Conference. Toronto, Ontario, Canada (February)
- 2007 Role of the Pharmacist in Antimicrobial Stewardship, Greater London Infectious Diseases Pharmacy Group, London, England (November)
- 2007 Superinfection and Resistant Bacterial Infection: An Adverse Drug Event, Hammersmith Hospital Medical Grand Rounds, London, England (November)
- 2007 State of Affairs of United States Antimicrobial Stewardship Programs, Cardiff, Wales (November)
- 2007 Antimicrobial Pharmacogenomics: What is the Relevance? SISSA, Trieste, Italy (December)
- 2007 Pharmacokinetics and Pharmacodynamics of Prion Disease. Trieste, Italy (December)
- 2008 Keynote Speaker. Promoting HAART Adherence. International Association of Physicians in AIDS Care Annual Meeting, New Jersey (March)
- 2010 Role of the Pharmacist in Antimicrobial Stewardship, Keynote Address, Israel Society of Hospital Pharmacists
- 2011 Antimicrobial Stewardship, Swiss Society Hospital Pharmacists, Lausanne, Switzerland (May)
- 2011 Outcomes Associated with Antimicrobial Stewardship Programs, University of Basel, Basel, Switzerland (May)
- 2011 Evidence-based Medicine: The Role of the Pharmacist in the Interdisciplinary Training of Health Care Professionals,

Health Professional Education Quality (HPEQ) Project, Bali, Indonesia (December)

- 2011 Development of Partnership in Improving the Quality of Health Education. Health Professional Education Quality (HPEQ) Project, Bali, Indonesia (December)
- 2012 Role of the Clinical Pharmacist in Antimicrobial Stewardship, University of Basel Antibacterial Therapy-Basics, Problems and Solutions, Basel, Switzerland (May)
- 2012 Integration of Western Medications with Traditional Chinese Medicine, Bangkok (August)

#### NATIONAL

- 1985 Recent Advances in Nonrespiratory Critical Care Medicine. Drug Interactions in the Critically III Patient. American Thoracic Society Annual Meeting. Anaheim, California (May)
- 1985 Clinical Use of New Antibiotics. Therapeutic and Economic Considerations for Hospital Pharmacy. New Orleans, Louisiana (December)
- 1987 Therapeutic Equivalence. Pacific-Presbyterian Teleconference. San Francisco, California (May)
- 1987 Treatment of Gram-negative Infection. Oregon Society of Hospital Pharmacists Fall Seminar. Sun River, Oregon (October)
- 1987 Prophylactic Antibiotics in Surgery. Oregon Society of Hospital Pharmacists Fall Seminar. Sun River, Oregon (October)
- 1987 Newer Beta-lactams and Quinolone Antibiotics. American Society of Microbiology, Medical Technologist Section. Palm Springs, California (October)
- 1988 Concepts in the Treatment of Gram-negative Infection. Pacific-Presbyterian Teleconference. San Francisco, California (September)
- 1988 Treatment of Infection in the Immunocompromised Patient. Pacific-Presbyterian Teleconference. San Francisco, California (October)
- 1989 Oral Antimicrobials in the Treatment of Serious Infection. Pacific-Presbyterian Teleconference. San Francisco, California (March)
- 1989 Basic Principles in the Treatment of Infectious Diseases. Washington State Pharmacists Association. Seattle, Washington (August)
- 1989 Basic Principles in the Treatment of Infectious Diseases.

Good Samaritan Hospital and Medical Center. Portland, Oregon (August)

- 1989 Drug Interactions of Antivirals and Other Chronic Medications: Focus on Ganciclovir. The National AIDS Update. San Francisco, California (October)
- 1989 What is the Role of Serum Bactericidal Titers in the Treatment of Infection? American Society of Hospital Pharmacists Midyear Clinical Meeting. Atlanta, Georgia (December)
- 1990 New Concepts in the Treatment of Gram-negative Infection. Pacific-Presbyterian Teleconference. San Francisco, California (March)
- 1990 Balancing the Responsibilities with the Expectations of Clinical Faculty in the '90s. American Association of Colleges of Pharmacy Annual Meeting. Salt Lake City, Utah (July)
- 1990 Septic Shock 1990. Current Issues in Infectious Diseases for Clinical Pharmacists. San Francisco, California (August)
- 1990 Controversies in the Treatment of Fungal Infection. Lifeline Television Series. Houston, Texas (October)
- 1990 New Concepts in the Treatment of Gram-Negative Infection. University of Pacific Teleconference. San Francisco, California (May)
- 1990 Role of Amphotericin B in the Treatment of Fungal Infection. American Society of Hospital Pharmacists Annual Meeting. San Diego, California (June)
- 1990 Moderator, Update on the Treatment of Fungal Infection. ASHP Annual Meeting. San Diego (June)
- 1990 Use of Laboratory Tests in the Treatment of Infection. St. John's University School of Pharmacy. New York (June)
- 1991 Antiendotoxins in the Treatment of Gram-Negative Sepsis. Washington Society of Hospital Pharmacists Annual Meeting. Seattle (October)
- 1991 Human Clinical Trials with Antibodies Directed Against Endotoxin. Emerging Strategies for Management of Serious Bacterial Infections. New Orleans (December)
- 1992 Appropriateness of Use of Colony Stimulating Factors. New Biotech Medications: Rational Use and Financial Considerations for the 1990's. HPI Health Services. St. Louis (April)
- 1992 Antiendotoxins in the Treatment of Gram-Negative Sepsis. Veteran's Administration Teleconference. San Francisco (June)

- 1992 Correlates of Morbidity and Mortality in Sepsis with Lymphocytic Cytokines. Key Mediators in Sepsis and the Effects of Antibiotics. American College of Clinical Pharmacy Annual Meeting. Toronto (August)
- 1992 Today's Treatment of Infection in Transplant Patients. Advances in Transplantation. San Francisco, California (November)
- 1992 Clinical Pharmacy and Patient Outcomes: A Case Study Approach. American Society of Hospital Pharmacists Midyear Clinical Meeting. Orlando, Florida (December)
- 1993 Advances in the Pharmacotherapy of Infectious Diseases. 14th Annual Madison Clinical Conference. Madison, Wisconsin (March)
- 1995 Co-Chairman. Infectious Diseases in Clinical Practice. Snowmass, Colorado (January), San Francisco (April)
- 1995 Update on the Use of Antibacterials, Antifungals, and Antivirals. Infectious Diseases in Clinical Practice. Snowmass, Colorado (January), San Francisco (April)
- 1995 Principles of Antimicrobial Therapy. Federal Pharmacists Symposium. San Francisco (January)
- 1995 Problems with Antimicrobial-resistant Bacteria. American Society of Hospital Pharmacists Annual Meeting. Philadelphia (June)
- 1996 Update on Antibacterial, Antifungal, and Antiviral Agents.18th Annual Infectious Diseases in Clinical Practice. Vail (January)
- 1996 Surgical Antibiotic Prophylaxis. 18th Annual Infectious Diseases in Clinical Practice. Vail (January)
- 1996 Antibiotics in Pregnancy. 18th Annual Infectious Diseases in Clinical Practice. Vail (January)
- 1997 Antibacterial and Antifungal Agents. 19th Annual Infectious Diseases in Clinical Practice. Snowmass (January)
- 1997 Outpatient Therapy of Serious Infections. 19th Annual Infectious Diseases in Clinical Practice. Snowmass (January)
- 1998 Antibacterial, Antifungal and Antiviral Agents. 20th Annual Infectious Diseases in Clinical Practice. Park City (February)
- 1998 Contemporary Approaches to Managing Antibiotic Utilization. Infectious Diseases Society of America Annual Meeting. Denver (November)
- 1998 Antimicrobial Management and Cost Containment (Convener) Infectious Diseases Society of America

Annual Meeting. Denver (November)

1998	The Role of the Clinical Pharmacist in Antimicrobial
	Management. Infectious Diseases Society of America
	Annual Meeting. Denver (November)

- 1999 Antibacterial, Antifungal and Antiviral Agents. 20th Annual Infectious Diseases in Clinical Practice. Snowmass (February)
- 1998 Management of Nosocomial Infections in the ICU. Advances in Medical-Surgical Nursing Las Vegas (April)
- 1998 Impact of Clinical Pharmacy in Antimicrobial Management. Pharmacoeconomics: Infectious Diseases Teleconference (May)
- 1998 Clinical Pathways and Treatment Guidelines. A Critical Appraisal. Society of Infectious Diseases Pharmacists Annual Meeting State of the Art Lecture. San Francisco (September)
- 1998 Antimicrobials: Pharmacokinetics, New Drug Development and Resistance and Susceptibility Testing. Moderator. 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA (November)
- 2000 Antibacterial, Antifungal and Antiviral Agents. 21th Annual Infectious Diseases in Clinical Practice. Breckenridge (February)
- 2001 Antibacterial, Antifungal and Antiviral Agents. 22nd Annual Infectious Diseases in Clinical Practice. Breckenridge (February)
- 2001 The Sepsis Drugs are Dead. Or Are They? University of Utah Medical Grand Rounds (April)
- 2001 Antibiotic Use Policies: Do They Limit Resistance? American Society of Health Car Pharmacists Annual Meeting 2001. Los Angeles (June)
- 2001 Use of Antibiotics in the Treatment of Common Outpatient Infections. State University of California National Teleconference San Francisco(October)
- 2001 Infectious Diseases Pharmacist Consultation..Beyond Dosing Recommendations. Infectious Diseases Society of America Annual Meeting. San Francisco (October)
- 2002 HIV/AIDS: Past/Present/Future. Council of State Governments. San Francisco (July)
- 2003 Antimicrobial Agents I, II, III. Infectious Diseases in Clinical Practice. Snowmass, Colorado (February)
- 2003 Impact of New and Emerging Technologies on Medication Errors and Adverse Drug Events. American

	Society of Health Systems Pharmacists Midyear Clinical Meeting. New Orleans, LA (December)
2004	Physician Variation in Antiretroviral Use and Its Effects. NIH Office of Research Affairs Planning Group on Natural History and Epidemiology Research. Teleconference (January)
2004	Antimicrobial Agents I, II, III. Infectious Diseases in Clinical Practice. Kauai, HI (February)
2004	Landmarks in the Management in Infectious Diseases. American Pharmaceutical Association. Seattle, WA (March)
2004	Practical Development and Evaluation of Antimicrobial Intervention Programs. MAD ID 2004. Phoenix, AZ (May)
2004	The New Inpatient Antibiotics. West Coast Regional Meeting of the Society of Hospital Medicine. San Francisco (October)
2005	What is the Utility of Antimicrobial Intervention Programs? Infectious Diseases Grand Rounds, New York University (NYU), New York (January)
2005	Appropriate Use of Antibacterials in the Ambulatory Setting. Infectious Diseases in Clinical Practice. Kauai, HI (February)
2005	Antibacterial in the Hospital. Infectious Diseases in Clinical Practice. Kauai, HI (February)
2005	Antifungal Update. Infectious Diseases in Clinical Practice. Kauai, HI (February)
2005	Appropriate Use of Topical Antibacterial. Infectious Diseases in Clinical Practice. Kauai, HI (February)
2005	The Antimicrobial Pipeline. Sufficient or Not? American College of Clinical Pharmacy (October)
2006	Update on the Outpatient Use of Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2006	Appropriate Use of Inpatient Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2006	Newly Approved Antimicrobial Agents. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2006	Antifungal Update. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2006	Appropriate Use of Topical Antimicrobials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2006	Appropriate Use of Antibacterials in the Treatment of

Appropriate Use of Antibacterials in the Treatment of 2006 Upper Respiratory Tract Infection. American Association of Physician Assistants. San Francisco (May)

2007	Update on the Outpatient Use of Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2007	Appropriate Use of Inpatient Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2007	Newly Approved Antimicrobial Agents. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2007	Antifungal Update. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2007	Appropriate Use of Topical Antimicrobials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2008	Update on the Outpatient Use of Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2008	Appropriate Use of Inpatient Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2008	Antifungal Update. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
2008	Rise of Community-acquired MRSA Bone and Joint Infection in Children: What Does It Mean for the Orthpedic Surgeon? Pediatric Orthopedic Society of North American, American Society for Orthopedics Annual Meeting (San Francisco) (March)
2008	Specialty Pharmacy Practice. Health Care Management Conference. (Seattle, WA) (July)
2008	Prevention of Antimicrobial Adverse Events. UCSF Annual Management of Hospitalized Patients (San Francisco) (October)
2008	Treatment of MRSA and C. difficile in the Hospital Setting. UCSF Annual Management of Hospitalized Patients (San Francisco) (October)
2009	Update on the Outpatient Use of Antibacterials. Infectious Diseases in Clinical Practice. (Konai, HI) (February)
2009	Appropriate Use of Inpatient Antibacterials. Infectious Diseases in Clinical Practice. (Konai, HI) (February)
2009	Antifungal Update. Infectious Diseases in Clinical Practice. (Kona, HI) (February)
2009	Antimicrobial Stewardship Programs, New Jersey Clinical Epidemiology and Infection Control (November)
2009	Panel Discussant. Institute of Medicine/ RW Johnson Initiative on the Future of Nursing
2010	Update on the Outpatient Use of Antibacterials. Infectious Diseases in Clinical Practice. (Kona, HI) (February)

- 2010 Appropriate Use of Inpatient Antibacterials. Infectious Diseases in Clinical Practice. (Kona, HI) (February)
- 2010 Antifungal Update. Infectious Diseases in Clinical Practice. (Kona, HI) (February)
- 2011 Update on the Outpatient Use of Antibacterials. Infectious Diseases in Clinical Practice. (Maui, HI) (February)
- 2011 Appropriate Use of Inpatient Antibacterials. Infectious Diseases in Clinical Practice. (Maui, HI) (February)
- 2011 Antifungal Update. Infectious Diseases in Clinical Practice. (Maui, HI) (February)
- 2011 Guest Panelist Infectious Diseases Update, Pharmacist Letter Editorial Board Webinar
- 2011 How Schools of Pharmacy are Handling Making our Students Competent in BBW, REMS, and Core Measures. American College of Clinical Pharmacy Annual Meeting (Pittsburgh, PA) (October)
- 2011 Convener. Success, Bottlenecks, and the Future of Antimicrobial Drug Discovery. American Chemical Society Webinar (November)
- 2012 Update on the Outpatient Use of Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
- 2012 Appropriate Use of Inpatient Antibacterials. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
- 2012 Antifungal Update. Infectious Diseases in Clinical Practice. (Kauai, HI) (February)
- 2012 Antimicrobial Management of Outpatient Respiratory Tract Infection. Hot Topics in Primary Care. Jackson Hole, WY (July)
- 2012 What is the Impact of CA-MRSA in the Management of Skin and Soft Tissue Infection. Hot Topics in Primary Care. Jackson Hole, WY (July)
- 2012 New Concepts in the Antibacterial Treatment of UTI. Hot Topics in Primary Care. Jackson Hole, WY (July)
- 2012 Rational Use of Antibiotics in the Hospital Setting. UCSF Annual Management of Hospitalized Patients (San Francisco) (October)

#### REGIONAL AND OTHER INVITED PRESENTATIONS

- 1980 Altered Drug Pharmacokinetics in Thyrotoxicosis. City of Hope Rational Therapeutics Seminar. Costa Mesa, California (September)
- 1980 Antibiotic Use in Periodontics. UCSF School of Dentistry,

	F
	Division of Periodontics. San Francisco, California (May)
1980	Athletics and the Use of Drugs. Northern California Society of Hospital Pharmacists. California (February)
1981	Newer Concepts in Antibiotic Therapy. San Francisco, California (June)
1981	Respiratory Drugs in the ER - An Update. California Association of Emergency Room Physicians Annual Meeting. San Francisco, California (May)
1981	UCSF Continuing Education : Update on Antibiotic Therapy.
1983	A Pharmaceutical Renaissance. New Drugs Developed Through Recombinant DNA Technology. Moderator, California Society of Hospital Pharmacists. Los Angeles and San Francisco, California (November)
1983	Drug Improvement of Athletic Performance. UC Berkeley Extension, R.K. Davies Hospital. San Francisco, California (October)
1983	Drug Treatment of Hypertension. UC Irvine Hypertension Seminar. Long Beach, California
1983	Methanol Poisoning. UCSF Renal Grand Rounds (September)
1983	Update on Antibiotic Therapy. San Francisco Public Health Continuing Education in Nursing. San Francisco, California (March)
1984	Antimicrobial Therapy. Skyline College Respiratory Therapy. San Bruno, California (May)
1984	Drug Improvement of Athletic Performance. Bank of America Lecturer. San Francisco, California (August)
1984	Drug Improvement of Athletic Performance. UC Berkeley Extension, Continuing Education. Berkeley, California (September)
1984	Prophylactic Antibiotics in Surgery. Santa Rosa Community Hospital Grand Rounds. Santa Rosa, California (August)
1984	Respiratory Infections in Pediatrics, UCSF Continuing Education, Critical Care Core Curriculum in Nursing. San Francisco, California (June)
1985	Antimicrobial Therapy. Skyline College Respiratory Therapy. San Francisco, California (May)
1985	Concepts in Surgical Infection. Moderator, Golden Gate Society of Hospital Pharmacists. Oakland, California

1985 Drugs and the Athlete. Sports Medicine: An Overview.

(September)

UC Berkeley Extension. San Francisco, California (October)

- 1985 Hospital Control of Antibiotics. Santa Rosa Community Hospital Family Practice Grand Rounds. Santa Rosa, California (February)
- 1985 Imipenem Symposium, Moderator, UCSF Alumni Association. San Francisco, California (July)
- 1985 Infection in the Ventilated Patient. Respiratory Therapy Conference: Care of the Patient on Mechanical Ventilation. San Mateo, California (September)
- 1985 New Beta-lactams Therapeutic and Economic Considerations. Enloe Memorial Hospital. Chico, California (November)
- 1985 Prophylactic Antibiotics in Surgery. Formulary Decisions - An Emphasis on Third Generation Cephalosporins. Tricounty Pharmacists Association. Ventura, California (July)
- 1986 Antibiotic Update 1986, Skyline College Respiratory Therapy. San Francisco, California (May)
- 1986 Current Trends and Practical Applications in Hospital Pharmacy Management. Moderator, Golden Gate and Diablo Societies of Hospital Pharmacy. San Francisco, California (May)
- 1986 Drug Improvement of Athletic Performance. Brown Bag Luncheon Lecture. University of California, San Francisco (May)
- 1986 Drug Improvement of Athletic Performance. UC Berkeley Extension. San Francisco, California (November)
- 1986 New Developments in Outpatient Antibiotic Therapy. Alta Bates Hospital. Berkeley, California (September)
- 1986 Trends in Antibiotic Therapy. Medical Grand Rounds, Highland Hospital. Oakland, California (June)
- 1987 Antibiotic Selection and Dosing in the Elderly. UC Davis Department of Infectious Diseases, Infectious Diseases Update. Sacramento, California (February)
- 1987 Antibiotic Update 1987. Skyline College, Respiratory Therapy. San Francisco, California (May)
- 1987 Cost-effectiveness of Antimicrobial Therapy. Medical Grand Rounds, Humana Hospital. San Leandro, California (November)
- 1987 Moderator, DRG's and Cost Effective Antimicrobial Therapy. Golden Gate Society of Hospital Pharmacists. Burlingame, California (February)

- 1987 Practical Aspects of Drug Utilization Review. CPhA Education Faire. Palm Springs (September)
- 1987 Practical Use of Antibiotics in Urologic Therapy. Urology Grand Rounds, UCSF (November)
- 1987 Prophylactic Antibiotics in Surgery. UCSF Department of Medicine, "Care of the Surgical Patient." San Francisco, California (March)
- 1987 Surgical Antimicrobial Prophylaxis. Medical Grand Rounds, Delta Memorial Hospital. Antioch, California (December)
- 1987 What is the Future Role of Aminoglycosides? Sacramento Medical Center/UC Davis Department of Pharmacy (May)
- 1988 Antimicrobials in the Outpatient Setting. Primary Care Medicine Grand Rounds. UCSF (December)
- 1988 Antimicrobials in Veterinary Medicine. Alameda County Veterinary Society. Oakland, California (September)
- 1988 Controversies in the Treatment of Intraabdominal Sepsis. UC Davis Continuing Education Seminar. Sacramento, California (June)
- 1988 New Antimicrobials: A Critical Evaluation. 17th Annual Clinical Conference, AMI-Community Hospital of Santa Cruz. Santa Cruz, California (July)
- 1988 New Concepts in Antimicrobial Therapy. Medical Grand Rounds, Sutter-Solano Hospital. Vallejo, California (January)
- 1988 New Concepts in the Outpatient Treatment of Infection. Alta Bates Hospital Education Series. Berkeley, California (February)
- 1988 Prophylactic Antimicrobials in Surgery. Medical Grand Rounds, Hayward Hospital. Hayward, California (March)
- 1988 Therapy of Nosocomial Infection. Marin General Hospital Nursing CE. San Rafael, California (February)
- 1988 Treatment of Gram-negative Infection. Medical Grand Rounds, Kaiser Santa Clara. Santa Clara, California (February)
- 1988 Trends in the Outpatient Treatment of Infection. San Mateo Pharmaceutical Association. San Mateo, California (August)
- 1989 Clinical Implications of Protein Binding on Antimicrobial Activity. San Francisco General Antimicrobial Pharmacology Series. San Francisco, California (February)

- 1989 Cost Effective Antimicrobial Therapy. Natividad Hospital. Salinas, California (May)
- 1989 Cost Effectiveness of Antibiotic Therapy: A Pharmacist's Role. North Coast Society of Hospital Pharmacists. Partners in Health Care: Cost Benefits of Clinical Pharmacy Services. Santa Rosa, California (April)
- 1989 New Concepts in the Antimicrobial Treatment of Gramnegative Infection. UCSF Continuing Education Series. Lake Tahoe, California (January)
- 1989 New Concepts in the Antimicrobial Treatment of Gramnegative Infection. UCSF Continuing Education Series. San Francisco, California (April)
- 1989 Oral Treatment of Serious Infection. California Society of Hospital Pharmacists Focus 89 (April)
- 1989 Oral Treatment of Serious Infection. UCSF Continuing Education Series. Lake Tahoe, California (January)
- 1989 Oral Treatment of Serious Infection. UCSF Continuing Education Series. San Francisco, California (April)
- 1989 Overview of the Critically III Patient, Critical Care Symposium. Golden Gate Society of Hospital Pharmacists. San Francisco, California (September)
- 1989 Prophylactic Antimicrobial Use in Maxillofacial Surgery. ENT Grand Rounds. San Rafael, California (December)
- 1990 Antibiotic Update. 11th Advances in Infectious Diseases. UCSF Medical Education. San Francisco, California (April)
- 1990 Antimicrobial Update. 4th Annual Symposium on Drug Therapy in The Elderly. Yountville, California (September)
- 1990 Antimicrobials in the Acute Care Setting. Kaiser Medical Grand Rounds. Richmond, California (July)
- 1990 Antimicrobials in the Hospital Setting. Sierra Society of Hospital Pharmacists. Fresno, California (September)
- 1990 Antimicrobials. Core Curriculum for Residents in Surgery. University of California. San Francisco, California (August)
- 1990 Concepts in the Treatment of Infection in the Critically III Patient. California Society of Hospital Pharmacists Focus 90. Long Beach, California (March)
- 1990 Cost-Effective Antimicrobial Therapy. IMI Hospital Medical Grand Rounds. Santa Cruz, California (May)
- 1990 New Developments in Vaccine and Antimicrobial Therapy. UCSF New Drugs Program. San Francisco,

California (January)/Incline Village, Nevada (March)

- 1990 Pharmacology of Agents Used in the Treatment of STD's. STD Comprehensive Course for Clinicians. San Francisco, California (September, 1990; February, 1991; September, 1991; February, 1992; March, 1992; June, 1992; September 1992; February 1993; May 1993)
- 1990 Ribavirin: More Than a Therapeutic Problem. CSHP Seminar '90. Santa Clara, California (October)
- 1990 The Pharmacist's Role in the Development and Implementation of Antibiotic Formularies. Golden Gate Society of Hospital Pharmacists. San Mateo, California (June)
- 1991 Antimicrobial Pharmacokinetics: Impact of Surgical Procedures. University of Southern California, Topics in Clinical Pharmacy Research. Los Angeles, California (March)
- 1991 Antimicrobial Update 1991. New Drugs Symposium, Veterans Administration Hospital at Martinez. Lake Tahoe (February), San Francisco (April)
- 1991 Antimicrobials in the Hospital Setting. North Coast Society of Hospital Pharmacists. Santa Rosa, California (March)
- 1991 Antimicrobials. Core Curriculum for Surgery Residents. University of California (November; November 1992; April 1993)
- 1991 Colony Stimulating Factors. From Laboratory to Clinical Application. PAPA Annual Meeting. San Francisco (September)
- 1991 Management of Urinary Tract Infection and Sexually Transmitted Diseases. Regional Kaiser Permanente Symposium. Pleasanton, California (July)
- 1991 Monoclonal Antiendotoxins in the Treatment of Gram-Negative Infection. Kaiser Hospital, San Rafael, California (September)
- 1991 New Strategies for the Dosing of Antimicrobials: Pharmacodynamic, Therapeutic, Toxicity and Cost Considerations. 9th Annual UC Davis Practical Update of Infectious Disease. Sacramento, California (February)
- 1991 Principles in the Selection of Antimicrobial Therapy. California Society of Hospital Pharmacists Focus 1991. Sacramento, California (April)
- 1991 Rational (and Irrational) Use of Antimicrobials. UCSF 12th Annual Advances in Infectious Diseases. San Francisco, California (April)

1992	Antiendotoxin Therapy in the Treatment of Gram- Negative Sepsis. University of California Davis Medical Center, Sacramento (March)
1992	Colony Stimulating Factors in Home Health Care CAHSAH Annual Symposium. Sacramento (April)
1992	Newer Oral Antibacterials. Los Gatos Community Hospital. Los Gatos, California (October)
1992	Quinolones and Macrolides. UCSF 13th Annual Advances in Infectious Diseases. San Francisco (May)
1993	Advances in Antifungal Therapy. Golden Gate Society of Hospital Pharmacists. San Francisco, California (May)
1993	Antibacterial Update. UCSF, VASF, SFGH, Medical Residents. San Francisco, California (June)
1993	Antibacterials in the Treatment of Gram-Negative Infection. Medical Residents Conference, St. Mary's Hospital. San Francisco, California (March)
1993	Antimicrobial Review. UCSF Pediatric Infectious Diseases Fellows. (September, October, November, December)
1993	Antimicrobial Update. Bay Area Infection Control Practitioners. Oakland, California (February)
1993	Antimicrobial Update. Oakland Kaiser Grand Rounds. Oakland (August)
1993	Cephalosporins. Los Gatos Community Hospital. Los Gatos, California (May)
1993	Moderator and Chairman, Current Concepts and Controversies in Infectious Diseases. Napa, California (April)
1993	Update on Antifungal Agents. San Rafael Kaiser Medical Grand Rounds. San Rafael (August)
1993	Use of Antimicrobials in Surgery Patients. UCSF Surgery Residents. (October)
1993	Use of Colony Stimulating Factors in the Prevention and Treatment of Infectious Diseases. Current Concepts and Controversies in Infectious Diseases. Napa, California (April)
1994	Antibacterial and Antifungal Update. UCSF Infectious Diseases Update. San Francisco (May).
1994	Antibiotic-resistant Organisms. Scholars in Science Program. City College of San Francisco (December)
1994	Antimicrobial Overview. UCSF Infectious Diseases Fellows (July)

- 1994 Antimicrobial Update. Medical Grand Rounds. Sonoma Valley Hospital, Sonoma (October)
- 1994 Basic Principles in the Treatment of Infectious Diseases. Federal Pharmacists Forum. San Francisco (February).
- 1994 Drugs Produced Via Biotechnology. Boom or Bust? UCSF Brown Bag Lecture Series (May).
- 1994 Moderator and Chairman, Challenges in Antibiotic Formulary Management. University of Southern California School of Pharmacy. Sacramento, California (April)
- 1994 Monoclonal Antibodies in the Treatment of Sepsis. ICU Grand Rounds (September)
- 1994 Update on the Management of Fungal Infection. Northern California Kaiser Continuing Education. Berkeley (May).
- 1994 Use of Oral Antimicrobials in the Treatment of Outpatient Respiratory Tract Infection. UCSF Pulmonary Grand Rounds (August)
- 1995 Antimicrobial Update. Central Valley Society of Hospital Pharmacists. Stockton (January)
- 1995 Antimicrobial Update. Diablo Society of Hospital Pharmacists. Oakland (April)
- 1995 Antimicrobials in the Treatment of Nosocomial Infection. Medical Grand Rounds. St. Mary's Hospital, San Francisco (March)
- 1995 Are the Sepsis Drugs Dead?. California Society of Hospital Pharmacists Focus 95. San Francisco (March)
- 1995 Controversies in General Surgical Prophylaxis. Pharmacology Update: Basic Science and Clinical Applications. Combined Anesthesia-Surgery Grand Rounds, University of California, San Francisco. San Francisco (February)
- 1995 Drug Therapy in Sepsis: Treatment Choices. Multiple Organ Dysfunction Syndrome. University of California, San Francisco (February)
- 1995 Formulary Decisions Regarding Antimicrobials. Catholic Hospitals Group. San Francisco (May)
- 1995 Newer Agents in the Treatment of Viral Infection. Advances in Internal Medicine. University of California, San Francisco. San Francisco (May) (June)
- 1995 Overview of Antibacterial Agents. Infectious Diseases Fellows Conference. University of California San Francisco. San Francisco (July)

1995	Pharmacology of Agents Used in the Treatment of Sexually Transmitted Diseases. County of San Francisco Practitioner Training Program. San Francisco (June)
1995	Prophylactic Antimicrobials in Surgery. Primary Care Series. University of California, San Francisco (March)
1995	Treatment of Fungal Infection. ICU Grand Rounds. University of California San Francisco, San Francisco (June)
1995	Treatment of Nosocomial Infection. ICU Grand Rounds. University of California San Francisco (July)
1995	Update on Antimicrobial Treatment of Bacterial Infection. Medical Grand Rounds. Oak Knoll Naval Hospital, Oakland (June)
1995	Update on the Antimicrobial Treatment of Surgical Infection. Surgery Grand Rounds. University of California at Mt. Zion, San Francisco (January)
1996	Controversies Associated with the Use of Oral Antibiotics. Merrihew Hospital Medical Grand Rounds, Martinez (August)
1996	Controversies in the Treatment of Fungal Infections. Quatra Society of Health Systems Pharmacists, San Jose (October)
1996	Outpatient Antibiotic Treatment of Infectious Diseases. University of California Continuing Medical Education, San Francisco (May)
1996	Update on the Use of Antimicrobials in the Inpatient Setting. North Coast Society of Hospital Pharmacists, Santa Rosa (September)
1997	Antimicrobial Resistance: Problems and Solutions. Novato Community Hospital Medical Grand Rounds, Novato (June)
1997	Antimicrobials in the Era of Drug Resistance. North Coast Society of Health Systems Pharmacists, Santa Rosa (April)
1997	Appropriate Use of Antimicrobials. UCSF Medical Residents, San Francisco (February)
1997	Newer Antimicrobial Agents-Where do they belong in our armamentarium? Eighteenth Annual Advances in Infectious Diseases. San Francisco (April)
1997	Optimal Treatment of Resistant Gram-Positive Pathogens. TriHospital Medical Grand Rounds, San Louis Obispo (June)
1007	Treatment of Multidrug-Resistant Bacterial Pathogens

1997 Treatment of Multidrug-Resistant Bacterial Pathogens. California Society of Health Systems Pharmacists, San Jose (October)

- 1997 Update in the Use of Oral Antimicrobials in the Ambulatory Setting. Highland Hospital Medical Grand Rounds, Oakland (May)
- 1997 Update on Antimicrobial Agents. New Drugs and Modern Concepts in Pharmacotherapy 1997. Incline Village (February), San Francisco (April)
- 1997 Update on the Treatment of Outpatient Respiratory Tract Infection. Golden Gate Society of Health Systems Pharmacists, San Francisco (June)
- 1998 Community-acquired Pneumonia. California Society of Hospital Pharmacists Focus 98, Tahoe (April)
- 1998 Controversies Associated with the Use of Antimicrobials in the Outpatient Setting. Nineteenth Annual Advances in Infectious Diseases. San Francisco (May)
- 1998 Diagnosis and Rationale for Management. UCSF Dept of Stomatology, San Francisco (February)
- 1998 Making Sense of Antibiotics for Community Acquired Pneumonia. UCSF Pulmonary Grand Rounds, San Francisco (October)
- 1998 Outpatient Use of Antibiotics. UC Berkeley Meyer Medical Lecture Program. Berkeley (October)
- 1998 Update on Antimicrobial Agents. New Drugs and Modern Concepts in Pharmacotherapy. University of the Pacific/VA, Tahoe (March), San Francisco (April)
- 1999 Antimicrobial Update. Warrick Hospital Medical Grand Rounds. Santa Rosa (February)
- 1999 Are We Creating a Superbug? UCSF Brown Bag Lecture Series. San Francisco (August)
- 1999 Control Strategies for the Use of Antibiotics. UCSF Emerging Infectious Diseases. San Francisco (February)
- 1999 New Antibiotics for Outpatient Therapy. Twentieth Annual Advances in Infectious Diseases. San Francisco (May)
- 1999 Oral Antimicrobial Update. Kaiser Permanente Medical Grand Rounds, San Francisco (March)
- 1999 Treatment of Infections in the ICU Setting. California Society of Hospital Pharmacists Focus 99, San Diego (March)
- 1999 Update on the Treatment of Gram-negative Infections in the Intensive Care Unit. Golden Gate Society of Health Systems Pharmacists, San Francisco (June)
- 2000 Antibiotic Resistance. What is the Risk to the Community? Center for Health and Community and

Center for Consumer Self Care (December)

- 2000 Antifungal Therapy in HIV. UCSF Positive Health Program (October)
- 2000 Antimicrobial Control in the Nosocomial and Community Setting. CPhA Education Faire, Pasadena (September)
- 2000 Appropriate Use of the Newer Antimicrobial Agents. UCSF Advances in Infectious Diseases. San Francisco (May, June)
- 2000 Bacterial Resistance and Its Impact Upon Antibiotic Selection. 17th Annual Combined General Assembly Meeting Northern California Branch of the American Society for Microbiology (November)
- 2000 Introduction to Antimicrobial Therapy (UCSF, VAMC, SFGH Medical Residents) (January)
- 2000 New Antibiotics. UCSF Management of the Hospitalized Patient. San Francisco (October)
- 2000 Newer Antibiotics in the Hospital Setting UCSF Annual Medical Update for Hospitalists (October)
- 2000 Outpatient Antimicrobial Therapy. UCSF Twenty First Annual Advances in Infectious Diseases. San Francisco (May)
- 2000 What is the Risk of Antibacterial Resistance? UCSF School of Pharmacy Homecoming 2000 (November)
- 2001 Antibiotic Utilization Strategies 8th Annual Epidemiology and Prevention of Infectious Diseases, San Francisco (February)
- 2001 Antibiotics in Agriculture: Impact Upon Antimicrobial Selection in the Treatment of Infection. San Francisco Medical Society Antibiotics and Agriculture Invitational Leadership Forum.. San Francisco (June)
- 2001 Antibiotics in the ICU. UCSF School of Nursing CE. (November)
- 2001 Antifungals in Pediatric Bone Marrow Transplant. Pediatric Bone Marrow Transplant Grand Rounds (October)
- 2001 Antimicrobial Control Strategies. California Association Practitioners in Infection Control Advanced Practice Conference San Diego (October)
- 2001 Appropriate Antibiotic Selection (Kaiser San Francisco Medical Grand Rounds) (September)
- 2001 Impact on Antimicrobial Selection in Treatment of Human Infection. Antibiotics and 2001Agriculture Leadership Forum. San Francisco Medical Society (June)

- 2001 Introduction to Antimicrobial Therapy (UCSF, VAMC, SFGH Medical Residents) (January)
- 2001 Introduction to Antimicrobial Therapy (UCSF, VAMC, SFGH Medical Residents) (July)
- 2001 Introduction to Antimicrobial Therapy (UCSF, VAMC, SFGH Medical Residents) (November)
- 2001 Outpatient Antimicrobial Therapy Parts I and II. 22nd Advances in Infectious Diseases San Francisco (May)
- 2001 Overview of Newer Agents in the Treatment of Sepsis. American College of Clinical Pharmacy, Southern California Chapter. (September)
- 2001 Principles of Antiinfective Therapy (Federal Pharmacists Symposium) (January)
- 2001 Selection of Antibiotics in the Critical Care Setting UCSF Critical Care Fellows and Residents Conference (Every Quarter)
- 2001 The Sepsis Drugs ar Dead. Or Are They? California Society of Health Systems Pharmacists Seminar 2001. San Jose (October)
- 2002 Antibiotic Resistance and Antibiotic Control Strategies 9th Annual Epidemiology and Prevention of Infectious Diseases, San Francisco (February)
- 2002 Antibiotics for Gram Negative Infection. UCSF Clinical Microbiology Continuing Education for Medical Technologists (January)
- 2002 Appropriate Use of Antibacterials in Outpatient Respiratory Tract Infection. Asian Health Care Services Medical Grand Rounds (Oakland) (October)
- 2002 Introduction to Antimicrobial Therapy (UCSF, VAMC, SFGH Medical Residents) (July, August)
- 2002 New Antimicrobial Agents. 50th Annual Advances in Internal Medicine. San Francisco (May, June)
- 2002 One Year Later, What is the Role of Activated Protein C? California Society of Health Systems Pharmacists Seminar 2002. Anaheim (October)
- 2002 Outpatient Antimicrobial Therapy Parts I and II.. 23rd Annual Advances in Infectious Diseases. San Francisco (May)
- 2002 Pharmacologic Management of the Septic Patient. San Mateo County Medical Center Medical Grand Rounds (January)
- 2002 Principles of Infectious Diseases. Federal Pharmacists Annual Conference (January)

- 2002 Selection of Antibiotics in the Critical Care Setting UCSF Critical Care Fellows and Residents Conference (Every Quarter)
- 2002 The Threat of Antibiotic Resistance: Fact or Fiction? UCSF Brown Bag Series (April)
- 2002 Treating Pneumonia and UTIs. Geriatrics 2002: Updates for Primary Care Practice. San Francisco (May)
- 2002 Use of Antifungals in Pediatric Bone Marrow Transplant. Pediatric Bone Marrow Transplant Conference (December)
- 2002 What is the Risk of Antibacterial Resistance? California Department of Consumer Affairs and UCSF Center for Consumer Self Care Hot Topics in Pharmacy Series. Sacramento (October)
- 2002 What is the Risk of Bacterial Resistance? Marin County Dental Association (March)
- 2003 Antibiotics for Fungal Infection. UCSF Clinical Microbiology Continuing Education for Medical Technologists (May)
- 2003 Antibiotics in the ICU: Resistance, Rotation, and More Resistance. Intensive Care Medicine for the Non-Intensivist. San Francisco (October)
- 2003 Controversies in the Treatment of Outpatient Respiratory Tract Infection. Geriatrics 2003: Updates for Primary Care Practice. San Francisco (May)
- 2003 Introduction to Antimicrobial Therapy (UCSF, VAMC, SFGH Medical Residents) (October)
- 2003 Outpatient Antimicrobial Therapy Part I and Part II. Advances in Infectious Diseases: New Directions for Primary Care. San Francisco (April)
- 2003 Priniciples in Infectious Diseases. Federal Pharmacists Seminar (January)
- 2003 Selection of Antibiotics in the Critical Care Setting UCSF Critical Care Fellows and Residents Conference (Every Quarter)
- 2003 Surgical Antibiotic Prophylaxis. CMRI Surgical Infection Prevention Collaborative. Sacramento (November)
- 2003 The Role of Antimicrobial Dosing in Efficacy and Toxicity During Treatment of Infectious Diseases. 21st Annual UC Davis Infectious Diseases Conference. Sacramento (February)
- 2003 Update in Antimicrobials. 31st Annual Advances in Internal Medicine. San Francisco (May) (June)

2003	Update on Antimicrobial Therapy. 15th Annual New Drugs & Modern Concepts in Pharmacotherapy. Lake Tahoe (March), San Francisco (April)
2003	What is the Risk of Antibacterial Resistance? Osher Center and Center for Consumer Self Care (October)
2004	Antibacterial Resistance and New Antibacterials. UCSF Clinical Microbiology, CMT continuing education. (December)
2004	Antifungal Medications in the Immune Compromised Patient. UCSF Pediatric Infectious Diseases Grand Rounds (December)
2004	Appropriate Use of Outpatient Antibacterial Agents. Kaiser Permanente Medical Grand Rounds. San Francisco (December)
2004	Fromm Institute Medical Lecture Series (October)
2004	Impact of Antimicrobial Use on Antibacterial Resistance. UCSF Oral Surgery Grand Rounds (May)
2004	Molecule to Medicine: The Long Road from Drug Discovery to Lifesaving Medication.
2004	Outpatient Antimicrobial Therapy Part I and Part II. Advances in Infectious Diseases: New Directions for Primary Care. San Francisco (April)
2004	Outpatient Use of Antibiotics. Meyer Medical Lecture Program at University Health Services, University of California Berkeley (April)
2004	Principles in Infectious Diseases. Federal Pharmacists Seminar (February)
2004	Rational Use of Antibiotics for Common Infections. Annual Primary Care Series. San Francisco (October)
2004	Role of the Pharmacist in the Management of HIV Patients. International Medical Program for AIDS Clinical Training University of California San Francisco (Februrary)
2004	Selection of Antibiotics in the Critical Care Setting UCSF Critical Care Fellows and Residents Conference (Every Quarter)
2004	The New (and Another Look at the Old) Hospital Antibiotics. Annual Hospitalist Conference, San Francisco (October)
2004	Update in Antimicrobials. Annual Advances in Internal Medicine. San Francisco (May)
2004	Update on Antifungal Medications. UCSF Heart and Lung Transplant Group (November)

2004	What is the Evidence for the Timing of Surgical Antibiotic Prophylaxis? CMRI Surgical Infection Prevention Collaborative. Teleconference (January)
2005	Antibacterial Use in Geriatric Patients. North Coast Society of Health-Systems Pharmacists (November)
2005	Antibiotic Update. Advances in Internal Medicine. San Francisco (June)
2005	Antibiotics in the Outpatient Setting. Advances in Infectious Diseases. New Directions for Primary Care. San Francisco (April)
2005	Antifungal Agents. Advances in Infectious Diseases. New Directions for Primary Care. San Francisco (April)
2005	Antimicrobial Update. New Drugs and Modern Concepts in Pharmacotherapy 2005. San Francisco (March)
2005	Appropriate Use of Outpatient Antibacterial Agents. Kaiser Permanente Medical Grand Rounds. San Francisco (December)
2005	Avian Flu. Antiviral Manufacturing, Resistance, and Toxicity. UCSF International Global Health Symposium. (December)
2005	Principles in Infectious Diseases. Federal Pharmacists Seminar (February)
2005	Surgical Antibacterial Prophylaxis. UCSF Orthopaedic Surgery Grand Rounds (September)
2005	Surgical Antibacterial Prophylaxis. UCSF Cardiothoracic Surgery Grand Rounds (August)
2005	Surgical Antibacterial Prophylaxis. UCSF Vascular Surgery Grand Rounds
2006	Antibacterial Pipeline: Promise or Peril. UCSF Oral Maxifacial Surgery Medical Grand Rounds (February)
2006	Antibacterial Resistance: Problems and Solutions. UCSF Medical Grand Rounds (January)
2006	Antibiotics in the Outpatient Setting. Advances in Infectious Diseases. New Directions for Primary Care. San Francisco (April)
2006	Antimicrobial Update. Seminar 2006 California Society of Health-Systems Pharmacists, Sacramento (October)
2006	Antiviral Update. UCSF Pediatric Infectious Diseases Fellows (January)
2006	Appropriate Use of Antibacterials in the Critical Care Setting. UCSF ICU Fellows (January)

2006 Controversies in the Antibacterial Treatment of Infection.

	Annual Hospitalist Conference, San Francisco (October)
2006	Controversies in the Management of Gram Negative Pneumonia UCSF Pulmonary Grand Rounds (February)
2006	Controversies in the Treatment of Gram Negative Infection. Childrens Hospital Medical Grand Rounds. Oakland, CA (January)
2006	Division of Infectious Diseases Weekly Conference Twice Yearly Presentations
2006	Principles in Infectious Diseases. Federal Pharmacists Seminar (January)
2006	What is the Role of the New Antimicrobials in the Treatment of Infection? Advances in Internal Medicine San Francisco (May) (June)
2007	Antibiotics in the Outpatient Setting. Advances in Infectious Diseases. New Directions for Primary Care. San Francisco (April)
2007	Division of Infectious Diseases Weekly Conference Twice Yearly Presentations
2008	Division of Infectious Diseases Weekly Conference Twice Yearly Presentations
2008	Management of Antibacterial Resistant Gram Negative Urinary Tract Infection. UCSF Urology Grand Rounds
2008	Keynote Speaker. The Future of Pharmacy. Northern California Pre-Pharmacy Symposium, Berkeley (April)
2009	Antibiotics in the Outpatient Setting. Advances in Infectious Diseases. New Directions for Primary Care. San Francisco (May)
2009	Controversies in the Management of Clostridium difficile Disease. UCSF Surgery Grand Rounds
2009	Division of Infectious Diseases Weekly Conference Twice Yearly Presentations
2010	Clinical Pearls in Infectious Diseases California Society Health Systems Pharmacists Seminar 2010 San Francisco (October)
2010	Division of Infectious Diseases Weekly Conference Twice Yearly Presentations
2010	Superinfection and Infection Due to Resistant Bacteria. An Adverse Drug Event? California Society Health Systems Pharmacists Seminar 2010 San Francisco (October)
2011	Challenges and Opportunities for the Clinical Preceptor. San Diego Residents Collaborative, San Diego (November)

- 2011 Rational Use of Outpatient Antibacterials. UCSF Emergency Medical Residents Conference (November)
- 2011 Hot Topics: Antimicrobial Dosing in Renal Disease. UCSF Renal Grand Rounds (November)
- 2011 Developing Leadership in Institutional Pharmacy Practice. Bay Area Directors of Pharmacy Assembly (January)
- 2012 Succession Planning. California Society Health-Systems Pharmacists Seminar 2011, Anaheim (November)
- 2012 Update: Influenza and Pertussis. California Society Health-Systems Pharmacists, South Lake Tahoe, (January)
- 2012 Antibiotics in the Outpatient Setting. Advances in Infectious Diseases. New Directions for Primary Care. San Francisco (April)
- 2012 Work-Life Balance. California Society Health-Systems Pharmacists Seminar 2012, Las Vegas (October)
- 2012 Rational Use of Antibiotics in the Hospital Setting. UCSF Hospital Medicine Grand Rounds

## **GOVERNMENT AND OTHER PROFESSIONAL SERVICE**

Listed under Service to Professional Organizations

# UNIVERSITY AND PUBLIC SERVICE

## UNIVERSITY SERVICE

#### UC SYSTEM-WIDE

2003 - 2004	University of California Committee on Academic Personnel	Campus Representative
2004 - 2005	University of California Committee on Academic Personnel	Vice Chairman
2008 - 2009	UC School of Global Health Global Health Senior Advisory Committee	Member
2012 -	Health Science Committee	Member
UCSF CAMPU	<u>S-WIDE</u>	
1982 - 1988	Long Teaching Award Committee	Member
1987 - 1992	UCSF Technical Advisory Committee on AIDS	Member
1987 - 1987	Milberry Union Advisory Committee	Member

1989 - 1989	UCSF 150th Anniversary Education Outreach Subcommittee: Drug Abuse	Member
1989 - 1989	Ad Hoc Committee for Change of Series: Professor of Clinical Pharmacy, School of Pharmacy	Member
1989 - 1989	Long Teaching Award Committee	Chairman
1992 - 1992	Ad Hoc Review Committee for Promotion	Member
1993 - 1993	Ad Hoc Review Committee for Promotion	Chair
1994 - 1994	Ad Hoc Review Committee for Promotion	Member
1994 - 1994	Working Group on the Relationship of Clinical Services to Education and Research	Member
1994 - 1994	UCSF Early Academic Outreach Program	Advisor
1995 - 1995	Ad Hoc Review Committee for Promotion	Chair
1996 - 1996	UCSF Early Academic Outreach Program	Advisor
1996 - 2003	Chancellor's Advisory Board on AIDS and Other Infectious Diseases	Member
1996 - 1996	Innovations in Health Sciences Education ITD Grants Review Committee	Member
1998 - 1998	Ad Hoc Review Committee for Promotion	Chair
1998 - 2000	Parnassus Space Committee	Member
1998 - 2000	Academic Senate Privilege and Tenure Committee	Member
1998 - 2000	Academic Senate Town Hall Planning Group	Member
1999 - 1999	Ad Hoc Review Committee for Promotion	Chair
1999 - 1999	Presentations to UC Regents and Sacramento Senate hearing regarding the UCSF-Stanford merger	Presenter
1999 - 2001	Academic Senate Committee on Clinical Affairs	Member
1999 - 2006	UCSF Faculty Association	Board of Directors
2001 - 2001	General Clinical Research Center Advisory Committee	Member
2001 - 2001	Academic Senate Committee for Academic Personnel (CAP)	Member

2001 - 2001	Academic Senate Shared Governance Committee	Member
2001 - 2001	Department of Cellular and Molecular Pharmacology	Faculty Search
2002 - 2002	Cancer Research Institute	Stewardship Review
2002 - 2002	Department of Radiology	Stewardship Review
2002 - 2002	Womens Interagency HIV Study (WIHS)	Steering Group
2002 - 2002	Academic Senate Distinction in Teaching Award Committee	Chairman
2002 - 2002	Review Committee California AIDS Research Center Innovative Grant Program	Member
2002 - 2002	Microbial Pathogenesis Program	Member
2002 - 2002	Advisory Board UCSF Magazine	Member
2002 - 2002	Academic Senate Task Force on Faculty Recruitment, Retention, and Promotion	
2003 - 2003	Academic Senate Distinction in Teaching Award Committee	Chairman
2003 - 2004	Committee on Academic Personnel	Chairman
2003 - 2004	Academic Senate Coordinating Committee	Member
2003 - 2003	Search Committee Chair of Division of Infectious Diseases	Member
2003 - 2004	Stewardship Review Committee Department of Surgery	Member
2003 - 2004	Stewardship Review Committee Proctor Foundation	Member
2004 - 2004	Search Committee Associate Vice Chancellor	Member
2004 - 2005	Committee on Academic Personnel	Chairman
2004 - 2005	Academic Senate Coordinating Committee	Member
2005 - 2005	Committee for Collaborative Research Evaluation	Chairman
2005 - 2005	PAACTR Selection Committee	Member
2006 -	Pharmacy Leadership Institute Advisory Board	Member
2006 - 2006	K12 Selection Committee	Member

2007 -	Center for Translational and Policy Research on Personalized Medicine Advisory Board	Member
2008 - 2008	KL2 Selection Committee	Member
2008 - 2008 - 2011	CTSI Mentor Development Program Executive Committee, Global Health Sciences	Associate Director Member
2008 - 2011	Admissions Committee Global Health Sciences Masters Program	Member
2008 -	Clinical Translational Research Pathway Advisory Council	Member
2009 -	Member School of Medicine CTR Pathway Advisory Council	Member
2009 - 2010	iMedRIS Steering Committee	Member
2009 - 2010	Search Committee Director of CTSI	Member
2009 - 2010	Search Committee CTSI Clinical Research Center Director	Member
2010 - 2010	Search Committee, Dean School of Nursing	Member
2010 - 2010	Stewardship Review Committee School of Nursing	Chair
2010 -	Resource Allocation Program (RAP) Career Development Review Committee	Chair
2010 -	2010-12 Long Range Development Plan Oversight Committee	Member
2011 -	Lifetime Achievement in Mentoring Award Selection Committee	Member
2011 - 2012	LRDP Parnassus Breakout Task Force	Co-Chair
2011 -	LRDP Clinical Facilities Subcommittee	Member
2012 -	Search Committee Dean School of Pharmacy	Member
2012 -	Chancellors Executive Committee	Member
2012 -	Clinical Translational Science Institute Executive Board	Member
2012 -	Compensation Committee	Member
2012 -	Budget Committee	Member
SCHOOL OF	PHARMACY	
1980 - 1983	Admissions Committee	Member
1980 - presen	t Interviews for Admissions Committee	Member

1983 - 1985	Educational Policy Committee	Member
1984 - 1986	Executive Committee	Member
1986 - 1994	Student Status Committee	Member
1990 - 1994	Student Status Committee	Chair
1995 - 1995	Graduate Instruction and Research Committee	Member
1995 - 1997	Task Force on Long-term Modification of Core Curriculum	Member
1995 - 1997	Library Committee	Member
1996 - 1996	Pharmaceutical Chemistry/Pharmacology Cluster	Vice Chair
1998 - 2000	Curriculum Implementation Committee	Chair
1998 - 2001	Educational Policy Committee	Member
2000 - 2002	Admissions Committee	Member
2002 - 2003	Pharm.D/Ph.D. Graduate Task Force	Member
2006 - 2012	Faculty Awards Committee	Member
2012 -	Accreditation Self-study Committee	Member
2012 -	Faculty Council	Member
2012 -	School of Pharmacy Leadership Group	Member

## DEPARTMENTAL SERVICE

1979 - 1985	Research Committee	Member
1984 - 2000	Residency Selection Committee	Member
1994 - 1994	Strategic Planning Practice Group	Chair
1995 - 1995	Administration support for various projects such as grants, investigations, revenue generation	Vice Chair of Scholarship
1998 - 1998	Faculty Search Committee; Outcomes Position	Member
1998 - 1998	Faculty Search Committee; Clinical Position	Member
1999 - 1999	1st Annual Spring Research Seminar	Coordinator
2000 - 2000	2nd Annual Spring Research Seminar	Coordinator
2000 - 2000	Executive Committee, Center for Consumer Self Care	Member
2001 - 2001	3rd Annual Spring Research Seminar	Coordinator
2001 - 2001	Topics in Research Series	Coordinator
2001 - 2002	Faculty Search Committee	Member
2002 - 2002	4th Annual Spring Research Seminar	Coordinator
2003 - 2003	5th Annual Spring Research Seminar	Coordinator
2004 - 2004	6th Annual Spring Research Seminar	Coordinator

2004 - 2004Center for Consumer Self Care NewsletterEditorial Board2005 - 20057th Annual Spring Research SeminarCoordinator2006 - 20068th Annual Spring Research SeminarCoordinator2006 - 2010Residency Selection CommitteeMember

## SUMMARY OF SERVICE ACTIVITIES

I provide numerous lay public newspaper and magazine, as well as television and radio presentations in my specialty area and in the area of pharmacy practice.

# **TEACHING AND MENTORING**

#### TEACHING

#### FORMAL SCHEDULED CLASSES FOR UCSF STUDENTS

Qtr	Academic Yr	Course Number and Title	Teaching Contribution	Units	Class Size
F	1982 - 1983	Clinical Pharmacy 130; Therapeutics	Lecturer, Course Coordinator (Shared)	-	125
Sp	1982 - 1983	Clinical Pharmacy 132; Therapeutics	Lecturer (2)	-	125
F,W, Sp, S	1982 - 1983	Clinical Pharmacy 148; Cardiovascular Clerkship	Preceptor	-	8
F	1983 - 1984	Clinical Pharmacy 130; Therapeutics	Lecturer, Course Coordinator (Shared)	-	125
F,W, Sp, S	1983 - 1984	Clinical Pharmacy 148; Cardiovascular Clerkship	Preceptor	-	6
Sp	1983 - 1984	Clinical Pharmacy 132; Therapeutics	Lecturer (Shared)	-	120
S	1983 - 1984	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
F	1984 - 1985	Clinical Pharmacy 130; Therapeutics	Lecturer (Shared)	-	130
F,W, Sp, S	1984 - 1985	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1984 - 1985	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1984 - 1985	Clinical Pharmacy 132; Therapeutics	Lecturer (Shared)	-	130
Sp	1984 - 1985	Clinical Pharmacy 132; Therapeutics	Conference Leader (Shared)	-	12
F,W, Sp, S	1985 - 1986	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1985 - 1986	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1985 - 1986	Clinical Pharmacy 132; Therapeutics	Lecturer	-	130

Qtr	Academic Yr	Course Number and Title	Teaching Contribution	Units	Class Size
Sp	1985 - 1986	Clinical Pharmacy 132; Therapeutics	Conference Leader	-	12
F,W, Sp, S	1986 - 1987	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1986 - 1987	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1986 - 1987	Clinical Pharmacy 132	Lecturer	-	130
F,W, Sp, S	1987 - 1988	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1987 - 1988	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1987 - 1988	Clinical Pharmacy 132	Lecturer	-	130
F,W, Sp, S	1988 - 1989	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1988 - 1989	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1988 - 1989	Clinical Pharmacy 132	Lecturer	-	130
F,W, Sp, S	1989 - 1990	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1989 - 1990	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1989 - 1990	Clinical Pharmacy 132	Lecturer	-	130
F,W, Sp, S	1990 - 1991	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1990 - 1991	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1990 - 1991	Clinical Pharmacy 132	Lecturer	-	130
F,W, Sp, S	1991 - 1992	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1991 - 1992	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130
Sp	1991 - 1992	Clinical Pharmacy 132	Lecturer	-	130
F,W, Sp, S	1992 - 1993	Clinical Pharmacy 175.03; Infect. Diseases Clerkship	Preceptor	-	4
W	1992 - 1993	Pharmacology 134; Pharmacology	Lecturer, Course Coordinator (Shared)	-	130

Qtr	Academic Yr	Course Number and Title	Teaching Contribution	Units	Class Size
Sp	1992 - 1993	Clinical Pharmacy 132	Lecturer	-	130
F,W, Sp, S	1993 - 1994	Clinical Pharmacy 175.03	Preceptor	-	4
F	1993 - 1994	Pharmacology 134	Lecturer	-	130
W	1993 - 1994	Clinical Pharmacy 131	Co-coordinator	-	130
F,W, Sp, S	1994 - 1995	Clinical Pharmacy 175.03	Preceptor	-	4
F	1994 - 1995	Pharmacology 134	Lecturer	-	130
W	1994 - 1995	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	1995 - 1996	Clinical Pharmacy 175.03	Preceptor	-	4
F	1995 - 1996	Pharmacology 134	Lecturer	-	130
W	1995 - 1996	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	1996 - 1997	Clinical Pharmacy 175.03	Preceptor	-	4
F	1996 - 1997	Pharmacology 134	Lecturer	-	130
W	1996 - 1997	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	1997 - 1998	Clinical Pharmacy 175.03	Preceptor	-	4
F	1997 - 1998	Pharmacology 134	Lecturer	-	130
W	1997 - 1998	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	1998 - 1999	Clinical Pharmacy 175.03	Preceptor	-	4
F	1998 - 1999	Pharmacology 134	Lecturer	-	130
W	1998 - 1999	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	1999 - 2000	Clinical Pharmacy 175.03	Preceptor	-	4
F	1999 - 2000	Pharmacology 134	Lecturer	-	130
W	1999 - 2000	Clinical Pharmacy 131	Lecturer	-	130
W	1999 - 2000	Clinical Pharmacy 131	Conference Leader	-	12
F,W, Sp, S	2000 - 2001	Clinical Pharmacy 175.03	Preceptor	-	4
F	2000 - 2001	Pharmacology 134	Lecturer	-	130
W	2000 - 2001	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2001 - 2002	Clinical Pharmacy 175.03	Preceptor	-	4
F	2001 - 2002	Pharmacology 134	Lecturer	-	130
W	2001 - 2002	Clinical Pharmacy 131	Lecturer	-	130

Qtr	Academic Yr	Course Number and Title	Teaching Contribution	Units	Class Size
F,W, Sp, S	2002 - 2003	Clinical Pharmacy 175.03	Preceptor	-	4
F	2002 - 2003	Pharmacology 134	Lecturer	-	130
W	2002 - 2003	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2003 - 2004	Clinical Pharmacy 175.03	Preceptor	-	4
F	2003 - 2004	Pharmacology 134	Lecturer	-	130
W	2003 - 2004	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2004 - 2005	Clinical Pharmacy 175.03	Preceptor	-	4
F	2004 - 2005	Pharmacology 134	Lecturer	-	130
W	2004 - 2005	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2005 - 2006	Clinical Pharmacy 175.03	Preceptor	-	4
F	2005 - 2006	Pharmacology 134	Lecturer	-	130
W	2005 - 2006	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2006 - 2007	Clinical Pharmacy 175.03	Preceptor	-	4
F	2006 - 2007	Pharmacology 134	Lecturer	-	130
W	2006 - 2007	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2008 - 2009	Clinical Pharmacy 175.03	Preceptor	-	4
F	2008 - 2009	Pharmacology 134	Lecturer	-	130
W	2008 - 2009	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2009 - 2010	Clinical Pharmacy 175.03	Preceptor	-	4
F	2009 - 2010	Pharmacology 134	Lecturer	-	130
F	2009 - 2009	Clinical Pharmacy 155	Lecturer		120
W	2009 - 2010	Clinical Pharmacy 131	Lecturer	-	130
F,W, Sp, S	2010 - 2011	Clinical Pharmacy 175.03	Preceptor		4
F	2010 - 2010	Pharmacology 134	Lecturer		130
F	2010 - 2010	Clinical Pharmacy 155	Lecturer		120
W	2010 - 2010	Clinical Pharmacy 131	Lecturer		130
F	2010 -	Clinical Pharmacy 154.01	Lecturer		30
F, W, Sp, S	2011 - 2012	Clinical Pharmacy 175.03	Preceptor		4

Qtr	Academic Yr	Course Number and Title	Teaching Contribution	Units	Class Size
F	2011 - 2011	Pharmacology 134	Lecturer		130
F	2011 -	Clinical Pharmacy 155	Lecturer		120
F	2011 - 2011	Clinical Pharmacy 154.01	Lecturer		30
W	2012 - 2012	Clinical Pharmacy 134	Lecturer		130

## TEACHING NARRATIVE

My past and current teaching has been balanced between preceptorship of both pharmacy and medicine students, residents, fellows in the area of infectious diseases pharmacotherapy. I additionally have coordinated most of the School of Pharmacy clinical therapeutics courses and consistently provide lectures in a variety of courses offered by the School. Lastly, I consistently contribute to continuing education courses offered by UCSF, once again in the area of infectious diseases pharmacotherapy.

#### MENTORING

#### PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program or School	Role	Current Position
-	Average of 2- 8 annually since the time of my appointment			

## POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED

Dates	Name	Fellow	Faculty Role	Current Position
1983 - 1984	Roberta Wong, Pharm.D.	-	Mentor	
1983 - 1984	Margaret Carver, Pharm.D.	-	Mentor	
1984 - 1985	Angelo Giambrone, Pharm.D.	-	Mentor	
1984 - 1985	Bret Brodowy, Pharm.D.	-	Mentor	
1984 - 1985	Lisa Chun, Pharm.D.	-	Mentor	
1984 - 1985	Robert Batman, Pharm.D.	-	Mentor	
1984 - 1985	Mark Woods,	-	Mentor	

Dates	Name	Fellow	Faculty Role	Current Position
	Pharm.D.			
1985 - 1986	Kevin Rodondi, Pharm.D.	-	Mentor	
1985 - 1986	Dorothy Lim, Pharm.D.	-	Mentor	
1985 - 1986	Fran Aweeka, Pharm.D.	-	Mentor	
1986 - 1987	Kim Bergstrom	-	Mentor	
1986 - 1987	Bonnie Dugoni	-	Mentor	
1986 - 1987	Doris Sue	-	Mentor	
1986 - 1987	Jennifer Chan	-	Mentor	
1987 - 1988	Mary Patten	-	Mentor	
1987 - 1988	Candace Smith	-	Mentor	
1988 - 1989	Susan Oliva	-	Mentor	
1988 - 1989	Betsy Althause	-	Mentor	
1988 - 1989	Miranda Kung	-	Mentor	
1989 - 1990	Robin Corelli	-	Mentor	
1989 - 1990	Janet Haas	-	Mentor	
1989 - 1990	Susan Dreyfus	-	Mentor	
1990 - 1991	Essy Mozafarri	-	Mentor	
1990 - 1991	Annie Wong- Beringer	-	Mentor	
1991 - 1992	Michele Lauderman	-	Mentor	
1991 - 1992	Terri Pang	-	Mentor	
1992 - 1993	Daniel Quan	-	Mentor	
1993 - 1994	Lori Joe	-	Mentor	
1993 - 1994	Renu Singh	-	Mentor	
1994 - 1995	Michele Dishon	-	Mentor	
1994 - 1995	Judith Jones	-	Mentor	
1995 - 1996	Ken Linsky	-	Mentor	
1995 - 1996	Jeanne Lucich	-	Mentor	
1996 - 1997	Dominic Paletta	-	Mentor	
1996 - 1997	Lucy Maa	-	Mentor	
1998 - 2000	Jamie Kilar	-	Mentor	

Dates	Name	Fellow	Faculty Role	Current Position
1998 - 2000	Larissa Graff	-	Mentor	
1998 - 2000	Kimberly Botwin	-	Mentor	
1998 - 2000	Jill Burkiewicz	-	Mentor	
1998 - 2000	Jeannie Chan	-	Mentor	
1998 - 2000	Maria Monica	-	Mentor	
1999 - 2000	Lisa Borland	-	Mentor	
2000 - 2001	Frank Svete	-	Mentor	
2000 - 2001	Shareen El- Ibiary	-	Mentor	
2000 - 2001	Lisa Wong	-	Mentor	
2001 - 2002	Nancy Chang	-	Mentor	
2001 - 2002	Rosa Yeh	-	Mentor	
2002 - 2003	Lan Chau	-	Mentor	
2003 - 2004	Christie Robinson	-	Mentor	
2005 - 2006	Marcin Rychlewski	-	Mentor	
2008 - 2009	Zlatan Coralic	-	Mentor	
2009 - 2010	Lina Teng	-	Mentor	
2009 - 2010	Reetu Gupta	-	Mentor	
-	Fellows/Spec ialty Residents			
1986 - 1987	Michel Duroux	Pharmacy Infectious Diseases Fellow	Mentor	
1988 - 1989	Janice Tam	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1989 - 1990	Marcia Glick	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1990 - 1991	Robin Corelli	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1991 - 1992	Annie Wong- Beringer	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1992 - 1993	Meganne Kanatani	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1993 - 1994	Karen Kostiuk	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1993 - 1995	Erika Wolfe	Pharmacy Infectious Diseases Fellowship	Mentor	

Dates	Name	Fellow	Faculty Role	Current Position
1994 - 1995	Marjorie Robinson	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1995 - 1996	Andy Luber	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1996 - 1998	Vicky Dudas	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1997 - 1998	Alex Hilts	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1998 - 1999	Larissa Graff	Pharmacy Infectious Diseases Specialty Resident	Mentor	
1999 - 2000	Katherine Yang	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2000 - 2001	Katherine Yang	Pharmacy Infectious Diseases Fellowship	Mentor	
2000 - 2001	Mark Villman	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2001 - 2002	Timothy Jancel	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2002 - 2003	Marisa Mendez	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2003 - 2004	Conan MacDougall	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2004 - 2005	Daniel Deck	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2005 - 2006	Keith Teelucksingh	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2006 - 2007	Cindy Loffler	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2006 - 2007	Luther Gwaza	Fogarty Fellow	Mentor	
2006 - 2007	Tsitsi Monera	Fogarty Fellow	Mentor	
2007 - 2008	Dimple Patel	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2008 - 2009	Yelena Belkin	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2008 - 2010	Carla Meyer-	(Switzerland	Mentor	

Dates	Name	Fellow	Faculty Role	Current Position
	Massetti	Medication Outcomes Fellowship		
2009 - 2010	Reetu Gupta	Pharmacy Infectious Diseases Specialty Resident	Mentor	
2009 - 2010	Adam Frymoyer	Pediatric Clinical Pharmacology Fellowship	Mentor	
2009 - 2011	Suzanna Kussmaul	Pediatric Infectious Diseases Fellowship	Mentor	
2010 - 2010	Luther Gwaza	Fogarty Fellow	Mentor	
2010 - 2012	Christopher Burrell	Medication Outcomes Center Fellow	Mentor	
2010 - 2011	Dominic Chan	Pharmacy Infectious Diseases Specialty Resident		
2011 - 2012	Jennifer Curello	Pharmacy Infectious Diseases Specialty Resident		

# FACULTY MENTORING

Dates	Name	Position While Mentored	Mentoring Role	Current Position
2005 - 2011	Katherine Yang (K12 Award)		Mentor	
2006 - 2009	Jennifer Cocohoba (BIRCWH K12 Award)		Mentor	
2007 - 2008	Conan MacDougall (Masters in Clinical Research)		Mentor	
2008 - 2009	Christine Cheng (American Society Health Systems Pharmacists Junior Investigator Award)		Mentor	

# OTHER VISITING FACULTY SUPERVISED

-	Maria Swartling	Sweden
-	Daniel Thirion	Canada
-	Ahuva Lustig	Israel

# TEACHING AND MENTORING AWARDS AND NOMINATIONS

1981	Long Foundation Award for Excellence in Teaching, UCSF
1981	Pharmacy Residents Preceptorship Award, UCSF
1985	Pharmacy Residents Preceptorship Award, UCSF
1986	Long Foundation Award for Excellence in Teaching, UCSF Pharmacy Class of 1986
1987	Pharmacy Residents Preceptorship Award, UCSF
1988	Pharmacy Residents Preceptorship Award, UCSF
1989	Pharmacy Residents Preceptorship Award, UCSF
1992	Academic Senate Distinction in Teaching Award
1992	Commencement Speaker, Class of 1992, UCSF School of Pharmacy
1995	Pharmacy Residents Preceptorship Award, UCSF
1999	Long Prize for Excellence in Teaching
2005	Deans Award for Teaching Excellence
2006	Deans Award for Teaching Excellence
2007	Deans Award for Teaching Excellence
2007	Nominee, UCSF Faculty Mentoring Program Lifetime Achievement in Mentoring Award
2010	Recipient UCSF Faculty Mentoring Program Lifetime Achievement in Mentoring Award
2011	Deans Apples for Preceptor Award

# SUMMARY OF TEACHING AND MENTORING HOURS

-

Total anticipated hours of teaching: 500 hours

# **RESEARCH AND CREATIVE ACTIVITIES**

RESEARCH AWARDS	
CURRENT	
RAS Award 115205 (PI)	2010 - 2016
ACS	
State of California Medicaid DUR Review	\$3.6 million total
RFA-OD-09-006 (PI)	07/01/2010 - 06/30/2015
NIH	\$470,372 direct/yr1
Building Interdisciplinary Research Careers in Women's Health Program (K12)	\$2,500,000 total
PAST	
No Number (Co-PI)	1983 - 1983
Eli Lilly Co.	
Retrospective Review of Postoperative Sepsis in Vascular Surgery	\$15,200 total
No Number (PI)	1984 - 1984
Eli Lilly Co.	
Pharmacokinetics of Cefamandole during Vascular Surgery	\$28,335 total
No Number (Co-PI)	1984 - 1984
Beecham Laboratories	
Dose Dependent Pharmacokinetics of Ticarcillin	\$20,800 total
No Number (PI)	1984 - 1984
Pfizer Laboratories	
Interaction of Cefoperazone and Tobramycin, An In Vivo and In Vitro Analysis	\$32,959 total
No Number (PI)	1987 - 1987
Glaxo Laboratories	
Pharmacokinetics and Pharmacodynamics of Cefoperazone and Ceftazidime	\$28,500 total
No Number (PI)	1987 - 1987
Smith Kline Laboratories	
Serum Bactericidal Activity of Cefoxitin and Ceftizoxime	\$18,700 total
No Number (Co-PI)	1989 - 1989
Pfizer	

"Interaction of AZT and Fluconazole,"	\$100,000 total
No Number (PI)	1991 - 1991
Upjohn Effect of Timing of Administration on Antimicrobial Pharmacokinetics	\$28,000 total
No Number (PI)	1993 - 1993
Fujisawa	
<ul><li>(1) Stability of Metronidazole with Ceftizoxime.</li><li>(2)</li><li>Penetration of Ceftizoxime into Brain Abscess</li></ul>	\$14,000 total
No Number (co-PI)	1993 - 1993
Pfizer	
Efficacy of E5 Monoclonal Antibody in the Treatment of Gram-Negative Sepsis	\$85,000 total
No Number (PI)	1994 - 1994
Merck	
Comparison of High and Low Dose Pharmacokinetics of Tobramycin in Cystic Fibrosis Patients	\$3,000 total
No Number (PI)	1994 - 1994
Merck	
Outcomes Associated with Pharmacist Antimicrobial Interventions.	\$10,000 total
No Number (co-PI)	1994 - 1994
Merck	
Antibacterial-associated Endotoxin Release and Lung Injury	\$19,000 total
No Number (PI)	1994 - 1994
Janssen	
Correlation of Itraconazole Serum Levels with Outcomes	\$10,000 total
No Number (PI)	1995 - 1995
Merck	
Epidemiology of Gram-negative Bacteremia in Critical Care Units. Formation of Critical Pathways	\$25,000 total
No Number (co-PI)	1995 - 1995
Merck	
Evaluation of the Use of Microbiology and Antimicrobials in the Neutropenic Patient	\$25,000 total
No Number (PI)	1996 - 1996

Ceftriaxone in the Oupatient Management of Staphylococcal Osteomyelitis       \$20,000 total         No Number (PI)       1996 - 1996         The Liposome Company       Risk Factors for Amphotericin-Induced Nephrotoxicity       \$50,000 total         No Number (co-PI)       1996 - 1996         Computer-Assisted Instruction Grant. UCSF Interactive Learning Center       1997 - 1997         Development of an Antiretroviral Algorithm.       \$5,000 total         No Number (PI)       1997 - 1997         Rhone Poulenc Rorer       Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.         No Number (PI)       1997 - 1997         Amerinet Corporation       \$14,000 total         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outomes in Community Acquired Pneumonia.       \$14,000 total         No Number (PI)       1998 - 1998         Abbott       Oral Antimicrobial Usage in Community-acquired         Oral Antimicrobial Usage in Community-acquired Pneumonia.       \$25,000 total         No Number (PI)       2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Preumonia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       \$25,000 total <td< th=""><th>Roche</th><th></th></td<>	Roche	
The Liposome Company         Risk Factors for Amphotericin-Induced Nephrotoxicity       \$50,000 total         No Number (co-PI)       1996 - 1996         Computer-Assisted Instruction Grant. UCSF Interactive       Learning Center         Development of an Antiretroviral Algorithm.       \$5,000 total         No Number (PI)       1997 - 1997         Rhone Poulenc Rorer       Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.         No Number (PI)       1997 - 1997         Amerinet Corporation       \$14,000 total         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       \$14,000 total         No Number (PI)       1998 - 1998         Abbott       000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Pidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxosmithKline       \$25,000 total         No Number (PI)       2002 - 2002         GlaxosmithKline       \$25,000 total         No Number (PI)       2002 - 2002         GlaxosmithKline       \$25,000 total         No Number (PI)       2002 - 2002         GlaxosmithKline <t< td=""><td></td><td>\$20,000 total</td></t<>		\$20,000 total
Risk Factors for Amphotericin-Induced Nephrotoxicity       \$50,000 total         No Number (co-PI)       1996 - 1996         Computer-Assisted Instruction Grant. UCSF Interactive       1997 - 1997         Learning Center       1997 - 1997         Development of an Antiretroviral Algorithm.       \$5,000 total         No Number (PI)       1997 - 1997         Rhone Poulenc Rorer       Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.         No Number (PI)       1997 - 1997         Amerinet Corporation       Survey of Antimicrobial Use Patterns and Patient         Survey of Antimicrobial Usage in Community-acquired Pneumonia.       \$14,000 total         No Number (PI)       1998 - 1998         Abbott       2000 - 2000         Oral Antimicrobial Usage in Community-acquired Pneumonia.       \$7,000 total         No Number (PI)       2000 - 2000         SmithKline       \$25,000 total         Intra - and interday variability of valacyclovir oral       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       11/30/2007         NiH/NIAID       12/01/2002 - 11/30/2007         Women's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004	No Number (PI)	1996 - 1996
No Number (co-PI)       1996 - 1996         Computer-Assisted Instruction Grant. UCSF Interactive Learning Center       \$5,000 total         Development of an Antiretroviral Algorithm.       \$5,000 total         No Number (PI)       1997 - 1997         Rhone Poulenc Rorer       Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.         No Number (PI)       1997 - 1997         Amerinet Corporation       Survey of Antimicrobial Use Patterns and Patient         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       \$14,000 total         No Number (PI)       1998 - 1998         Abbott       \$7,000 total         Oral Antimicrobial Usage in Community-acquired       \$7,000 total         Pneumonia.       \$2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Intra - and interday variability of valacyclovir oral       \$25,000 total         Intra - and interday variability of valacyclovir oral       \$25,000 total         No Number (PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       314,613,801 total	The Liposome Company	
Computer-Assisted Instruction Grant. UCSF Interactive Learning Center       \$5,000 total         Development of an Antiretroviral Algorithm.       \$5,000 total         No Number (PI)       1997 - 1997         Rhone Poulenc Rorer       Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.       \$30,000 total         No Number (PI)       1997 - 1997         Amerinet Corporation       \$14,000 total         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       \$14,000 total         No Number (PI)       1998 - 1998         Abbott       2000 - 2000         Oral Antimicrobial Usage in Community-acquired       \$7,000 total         Pneumonia.       \$2000 - 2000         No Number (PI)       2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       11/201/2002 - 11/30/2007         NIH/NIAID       12/01/2002 - 11/30/2007         Women's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       2004 - 2004	Risk Factors for Amphotericin-Induced Nephrotoxicity	\$50,000 total
Learning Center       \$\$5,000 total         Development of an Antiretroviral Algorithm.       \$\$5,000 total         No Number (PI)       1997 - 1997         Rhone Poulenc Rorer       \$30,000 total         Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.       \$30,000 total         No Number (PI)       1997 - 1997         Amerinet Corporation       \$14,000 total         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       1998 - 1998         No Number (PI)       1998 - 1998         Abbott       0ral Antimicrobial Usage in Community-acquired         Pneumonia.       \$7,000 total         No Number (PI)       2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       \$25,000 total         Intra- and interday variability of valacyclovir oral       \$25,000 total         No Number (PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       Thommen& apos;s Interagency HIV Study (WIHS) III	No Number (co-PI)	1996 - 1996
No Number (PI)       1997 - 1997         Rhone Poulenc Rorer       230,000 total         Compassionate Use of Quinupristin/Dalfopristin in the       \$30,000 total         Treatment of Vancomycin-resistant Enterococcal Infection.       1997 - 1997         No Number (PI)       1997 - 1997         Amerinet Corporation       1997 - 1997         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       1998 - 1998         No Number (PI)       1998 - 1998         Abbott       0ral Antimicrobial Usage in Community-acquired         Oral Antimicrobial Usage in Community-acquired       \$7,000 total         Pneumonia.       2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       1         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       12/01/2002 - 11/30/2007         RFA # Al-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       Women's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004       Abbott	•	
Rhone Poulenc Rorer       Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.       \$30,000 total         No Number (PI)       1997 - 1997         Amerinet Corporation       \$14,000 total         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       \$14,000 total         No Number (PI)       1998 - 1998         Abbott       0         Oral Antimicrobial Usage in Community-acquired       \$7,000 total         Pneumonia.       \$2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       \$25,000 total         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       \$25,000 total         RFA # Al-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       \$14,613,801 total	Development of an Antiretroviral Algorithm.	\$5,000 total
Compassionate Use of Quinupristin/Dalfopristin in the Treatment of Vancomycin-resistant Enterococcal Infection.\$30,000 totalNo Number (PI)1997 - 1997Amerinet Corporation\$14,000 totalSurvey of Antimicrobial Use Patterns and Patient Outcomes in Community Acquired Pneumonia.\$14,000 totalNo Number (PI)1998 - 1998Abbott0Oral Antimicrobial Usage in Community-acquired Pneumonia.\$7,000 totalNo Number (PI)2000 - 2000SmithKline Beecham Partners Program Epidemiology of VRE bacteremia.\$25,000 totalNo Number (PI)2002 - 2002GlaxoSmithKline\$25,000 totalIntra- and interday variability of valacyclovir oral bioavailability.\$25,000 totalRFA # AI-02-001 (Greenblatt R, PI)12/01/2002 - 11/30/2007NIH/NIAID\$14,613,801 totalNo Number (PI) 2004 - 20042004 - 2004Abbott\$16,000 total	No Number (PI)	1997 - 1997
Treatment of Vancomycin-resistant Enterococcal Infection.         No Number (PI)       1997 - 1997         Amerinet Corporation       \$14,000 total         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       \$14,000 total         No Number (PI)       1998 - 1998         Abbott       0ral Antimicrobial Usage in Community-acquired         Oral Antimicrobial Usage in Community-acquired       \$7,000 total         Pneumonia.       2000 - 2000         SmithKline Beecham Partners Program       2000 - 2000         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       1         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       \$25,000 total         RFA # AI-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         Women's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       4         Antimicrobial Usage in the Treatment of Community       \$16,000 total		
Amerinet Corporation       \$14,000 total         Survey of Antimicrobial Use Patterns and Patient       \$14,000 total         Outcomes in Community Acquired Pneumonia.       1998 - 1998         Abbott       1998 - 1998         Oral Antimicrobial Usage in Community-acquired       \$7,000 total         Pneumonia.       2000 - 2000         SmithKline Beecham Partners Program       2000 - 2000         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       1         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       12/01/2002 - 11/30/2007         NIH/NIAID       Yomen's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       2004 - 2004		\$30,000 total
Survey of Antimicrobial Use Patterns and Patient Outcomes in Community Acquired Pneumonia.\$14,000 totalNo Number (PI)1998 - 1998Abbott0ral Antimicrobial Usage in Community-acquired Pneumonia.\$7,000 totalNo Number (PI)2000 - 2000SmithKline Beecham Partners Program Epidemiology of VRE bacteremia.\$25,000 totalNo Number (PI)2002 - 2002GlaxoSmithKline Intra- and interday variability of valacyclovir oral bioavailability.\$25,000 totalRFA # Al-02-001 (Greenblatt R, PI)12/01/2002 - 11/30/2007NIH/NIAID Women's Interagency HIV Study (WIHS) III\$14,613,801 totalNo Number (PI) 	No Number (PI)	1997 - 1997
Outcomes in Community Acquired Pneumonia.         No Number (PI)       1998 - 1998         Abbott       0ral Antimicrobial Usage in Community-acquired         Pneumonia.       \$7,000 total         No Number (PI)       2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       1         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       \$25,000 total         RFA # AI-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         Women's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       \$16,000 total	Amerinet Corporation	
Abbott       Oral Antimicrobial Usage in Community-acquired       \$7,000 total         Pneumonia.       \$2000 - 2000         No Number (PI)       2000 - 2000         SmithKline Beecham Partners Program       \$25,000 total         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       1         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       \$25,000 total         RFA # AI-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       4bbott         Antimicrobial Usage in the Treatment of Community       \$16,000 total	•	\$14,000 total
Oral Antimicrobial Usage in Community-acquired Pneumonia.\$7,000 totalNo Number (PI)2000 - 2000SmithKline Beecham Partners Program Epidemiology of VRE bacteremia.\$25,000 totalNo Number (PI)2002 - 2002GlaxoSmithKline Intra- and interday variability of valacyclovir oral bioavailability.\$25,000 totalRFA # Al-02-001 (Greenblatt R, PI)12/01/2002 - 11/30/2007NIH/NIAID Women's Interagency HIV Study (WIHS) III\$14,613,801 totalNo Number (PI) 2004 - 20042004 - 2004Abbott Antimicrobial Usage in the Treatment of Community\$16,000 total	No Number (PI)	1998 - 1998
Pneumonia.2000 - 2000No Number (PI)2000 - 2000SmithKline Beecham Partners ProgramEpidemiology of VRE bacteremia.Epidemiology of VRE bacteremia.\$25,000 totalNo Number (PI)2002 - 2002GlaxoSmithKlineIntra- and interday variability of valacyclovir oral bioavailability.\$25,000 totalRFA # Al-02-001 (Greenblatt R, PI)12/01/2002 - 11/30/2007NIH/NIAID Women's Interagency HIV Study (WIHS) III\$14,613,801 totalNo Number (PI)2004 - 2004Abbott Antimicrobial Usage in the Treatment of Community\$16,000 total	Abbott	
SmithKline Beecham Partners Program         Epidemiology of VRE bacteremia.       \$25,000 total         No Number (PI)       2002 - 2002         GlaxoSmithKline       1000 - 2002         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       \$25,000 total         RFA # AI-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       2004 - 2004         Abbott       \$16,000 total		\$7,000 total
Epidemiology of VRE bacteremia.\$25,000 totalNo Number (PI)2002 - 2002GlaxoSmithKline1002 - 2002Intra- and interday variability of valacyclovir oral\$25,000 totalbioavailability.\$25,000 totalRFA # AI-02-001 (Greenblatt R, PI)12/01/2002 - 11/30/2007NIH/NIAID\$14,613,801 totalWomen's Interagency HIV Study (WIHS) III\$14,613,801 totalNo Number (PI)2004 - 2004Abbott\$16,000 total	No Number (PI)	2000 - 2000
No Number (PI)       2002 - 2002         GlaxoSmithKline       Intra- and interday variability of valacyclovir oral       \$25,000 total         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       12/01/2002 - 11/30/2007         RFA # AI-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       \$16,000 total	SmithKline Beecham Partners Program	
GlaxoSmithKline         Intra- and interday variability of valacyclovir oral       \$25,000 total         bioavailability.       \$25,000 total         RFA # AI-02-001 (Greenblatt R, PI)       12/01/2002 - 11/30/2007         NIH/NIAID       \$14,613,801 total         Women's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       \$16,000 total	Epidemiology of VRE bacteremia.	\$25,000 total
Intra- and interday variability of valacyclovir oral bioavailability.\$25,000 totalRFA # AI-02-001 (Greenblatt R, PI)12/01/2002 - 11/30/2007NIH/NIAID Women's Interagency HIV Study (WIHS) III\$14,613,801 totalNo Number (PI)2004 - 2004Abbott Antimicrobial Usage in the Treatment of Community\$16,000 total	No Number (PI)	2002 - 2002
bioavailability. RFA # AI-02-001 (Greenblatt R, PI) NIH/NIAID Women's Interagency HIV Study (WIHS) III No Number (PI) Abbott Antimicrobial Usage in the Treatment of Community \$16,000 total	GlaxoSmithKline	
NIH/NIAID         Women's Interagency HIV Study (WIHS) III         \$14,613,801 total         No Number (PI)         Abbott         Antimicrobial Usage in the Treatment of Community         \$16,000 total	· · ·	\$25,000 total
Women's Interagency HIV Study (WIHS) III       \$14,613,801 total         No Number (PI)       2004 - 2004         Abbott       4000 total         Antimicrobial Usage in the Treatment of Community       \$16,000 total	RFA # AI-02-001 (Greenblatt R, PI)	12/01/2002 - 11/30/2007
No Number (PI)2004 - 2004AbbottAntimicrobial Usage in the Treatment of Community\$16,000 total	NIH/NIAID	
Abbott Antimicrobial Usage in the Treatment of Community \$16,000 total	Women's Interagency HIV Study (WIHS) III	\$14,613,801 total
Antimicrobial Usage in the Treatment of Community \$16,000 total		2004 - 2004
	Antimicrobial Usage in the Treatment of Community	\$16,000 total

	Prepared: January 24, 2013
No Number (PI)	2004 - 2004
FirstDataBank	
Development of Patient Medication Monographs	\$268,000 total
No Number (PI)	2004 - 2004
ICMH Ltd	
Effect of I'm-Yunity on Liver Cytochrome P450 3A4 Enzyme Induction or Inhibition	\$100,000 total
P01 AG021601 (Investigator (Prusiner, Stanley B PI))	01/01/2004 - 05/31/2008
NIH/NIA	
Evaluation of pharmacological approaches in the treatment of prion disease.	\$4,041,334 total
D43 TW000003 (UCSF Principal Investigator)	2006 - 2007
NIH	
International AIDS Training Program (Zimbabwan herb- antiretroviral drug interactions)	\$24,000 total
R01NS057229 (Guglielmo Investigator)	2006 - 2009
NIH	
Tetracycline like drugs in the nonsurgical treatment of brain aneurysms.	
UL1 RR024131-01 (Co-director of the Research Mentor Group (McCune JM PI))	05/01/2007 - 06/30/2010
NIH	
Clinical Translational Science Institute (CTSI) at UCSF	\$16,667,534 total
D43 TW000003 (UCSF PI(Arthur Reingold UCB PI))	2010 - 2010
NIH	
International AIDS Training Program (Zimbabwan herb- antiretroviral drug interactions)	\$18,000 total

#### PEER REVIEWED PUBLICATIONS

1. Theophylline Elixir, Moxalactam, and a Disulfiram Reaction. K.R. Brown, B.J. Guglielmo, V.G. Pons, and R.A. Jacobs. *Ann. Int. Med.* **97**, 621-622 (1982).

2. Antibiotic Prophylaxis in Surgical Procedures. A Critical Analysis of the Literature. B.J. Guglielmo, D.C. Hohn, P.J. Koo, T.K. Hunt, R.C. Sweet, and J.E. Conte, Jr. *Arch. Surg.* **118**, 943-955 (1983).

3. Prolonged Diarrhea Secondary to Methyldopa Therapy. B.D. Quart and B.J. Guglielmo. *Drug Intell. Clin. Pharm.* **17**, 462 (1983).

4. Excessive Potassium Depletion with Metolazone and Furosemide. W.A. Kehoe and B.J. Guglielmo. *Clin. Pharm.* **2**, 304 (1983).

5. Iodine Toxicity in a Patient Treated by Continuous Povidone-Iodine Mediastinal Irrigation. P.L. Glick, B.J. Guglielmo, R.F. Tranbaugh, and K. Turley. *Ann. Thorac. Surg.* **39**, 478-480 (1985).

6. Comparative Pharmacokinetics of Low- and High-Dose Ticarcillin. B.J. Guglielmo, J.F. Flaherty, R. Batman, S.L. Barriere, and J.G. Gambertoglio. *Antimicrob. Ag. Chemother.* **30**, 359-360 (1986).

7. Pharmacokinetics of Cefoperazone and Tobramycin Alone and in Combination. B.J. Guglielmo, J.F. Flaherty, T.M. Woods, G. LaFollette, and J.G. Gambertoglio. *Antimicrob. Ag. Chemother.* **31**, 264-266 (1987).

8. Severe Hypersensitivity Reaction Upon Rechallenge With Trimethoprim-sulfamethoxazole in a Patient With AIDS. P.A. Arnold, B.J. Guglielmo, and H. Hollander. *Drug Intell. Clin. Pharm.* **22**, 43-45 (1988).

9. Effect of Protein Binding on Serum Bactericidal Activities of Ceftazidime and Cefoperazone in Healthy Volunteers. Y.W.F. Lam, M.H. Duroux, J.G. Gambertoglio, S.L. Barriere, and B.J. Guglielmo. *Antimicrob. Agents Chemother.* **32**, 298-302 (1988).

10. Comparison of Antibiotic Activity Using Serum Bactericidal Activity Over Time. B.J. Guglielmo and L.C. Rodondi. *Antimicrob. Agents Chemother.* **32**, 1511-1514 (1988).

11. We are Concerned About Ribavirin Exposure. M.J. Mahlmeister, B.J. Guglielmo, and R. Harrison. *Resp. Care* **33**, 809-810 (1988).

12. Assessing Exposures of Health-care Personnel to Aerosols of Ribavirin-California. R.J. Harrison, J. Bellows, D. Rempel, L. Rudolph, K. Kizer, A. Jin, B.J. Guglielmo, and B.B. Bernard. *Morbidity and Mortality Weekly Reports* **37**, 560-562 (1988).

13. Comparative Pharmacokinetics and Serum Inhibitory Activity of Clindamycin in Different Dosing Regimens. J.F. Flaherty, L.C. Rodondi, B.J. Guglielmo, J.C. Fleishaker, R.J. Townsend, and J.G. Gambertoglio. *Antimicrob. Agents Chemother.* **32**, 1825-1829 (1988).

14. CSF Penetration of Amphotericin B in AIDS Patients With Cryptococcal Meningitis. B. Dugoni, B.J. Guglielmo, and H. Hollander. *Clin. Pharm.* **8**, 220-221 (1988).

15. The Exposure of Health Care Workers to Ribavirin Aerosol. B.J. Guglielmo, R.A. Jacobs, and R.M. Locksley. *JAMA* **261**, 1880-1881 (1989).

16. Altered Pharmacokinetics of Antibiotics During Vascular Surgery. B.J. Guglielmo, T.A. Salazar, L.C. Rodondi, M. Carver, J. Goldstone, and R.J. Stoney. *Am. J. Surg.* **157**, 410-412 (1989).

17. Failure of Intravenous Vancomycin and Intravenous Metronidazole to Prevent or Treat Antibiotic-Associated Pseudomembranous Colitis. S. Oliva, B.J. Guglielmo, V.G. Pons, and R.A. Jacobs. *J. Infec. Dis.* **159**, 1154-1155 (1989).

18. Pharmacist-Managed Drug Therapy in California Hospitals. B.J. Guglielmo, B. Schweigert, and D.T. Kishi. *Am. J. Hosp. Pharm.* **46**, 1366-1369 (1989).

19. Effect of Surgical Blood Loss and Volume Replacement on Antibiotic Pharmacokinetics. D. Sue, T.A. Salazar, K. Turley, and B.J. Guglielmo. *Ann. Thor. Surg.* **47**, 857-859 (1989).

20. Microbiology and Antibiotics in Infectious Abdominal Emergencies. In *Emergency Medicine Clinics of North America*. J. Tam and B.J. Guglielmo **7**, 611-629 (1989).

21. Experience with Selective Reporting of Antimicrobial Susceptibility Test Results and Physician Prescribing Patterns. B.A. Brodowy, B.J. Guglielmo, Mary K. York, E.T. Herfindal, and G.F. Brooks. *Am. J. Hosp. Pharm.* **46**, 1816-1818 (1989).

22. Reply, The Exposure of Health Care Workers to Ribavirin Aerosol. B.J. Guglielmo, R.A. Jacobs, and R.M. Locksley. *JAMA* **262**, 1948 (1989).

23. Antimicrobial Therapy: Cost-benefit Considerations. B.J. Guglielmo and G.F. Brooks. *Drugs* **38**, 473-480 (1989).

24. What is the Clinical Role of Aerosolized Ribavirin? M.F. Hebert and B.J. Guglielmo. *DICP Ann. Pharmacother.* **24**, 735-738 (1990).

25. Antibiotic Prophylaxis in Cesarean Section. M. Glick and B.J. Guglielmo. *DICP Ann. Pharmacother.* **24**, 841-846 (1990).

26. Mediastinal Absorption of Povidone Iodine in Dogs. P. Glick, B.J. Guglielmo, M.E. Winter, W. Finkbeiner, and K. Turley. *J. Surg. Res.* **49**, 428-434 (1990).

27. Medication Usage Patterns in Patients with Human Immunodeficiency Virus Infection: A Comparison of Patient Reported Medication Usage with Medical Chart Review. R.L. Corelli, B.J. Guglielmo, J.E. Kapusnik-Uner, J.R. McMaster, and R.M. Greenblatt. *DICP Ann. Pharmacother.* **25**, 1374-1377 (1991).

28. Gram-negative Sepsis, the Sepsis Syndrome, and the Role of Antiendotoxin Monoclonal Antibodies. S.L. Barriere, B.J. Guglielmo. *Clin. Pharm.* **11**, 223-235 (1992).

29. Treatment of Funguria. A. Wong-Beringer, R.A. Jacobs, B.J. Guglielmo. *JAMA* 267, 2780-2785 (1992).

30. ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. S.L. Barriere, J. Connors, L.H. Danziger, J.T. DiPiro, J.F. Flaherty, B.J. Guglielmo, B. Kreter, R.P. Rapp. *Clin. Pharm.* **11**, 483-513 (1992).

31. Monoclonal Therapy for Bacteremic and Septic Patients. B.J. Guglielmo, J.P. Wiener-Kronish. *West J. Med.* **157**, 174 (1992).

**32**. Home Antibiotic Therapy for Streptococcal Endocarditis: A Call for a Controlled Trial. J.M. Colford, R.L. Corelli, J.W. Ganz, B.J. Guglielmo, R.A. Jacobs. *Am. J. Med.* **94**, 111-112 (1992).

33. Cost Benefits Associated with Once-Daily Parenteral Antibiotics. B.J. Guglielmo. *Pharmacoeconom Infect Dis.* (Editorial) **2** (1993).

34. Ceftizoxime Versus Vancomycin and Gentamicin in Neurosurgical Prophylaxis: A Randomized, Prospective, Blinded Clinical Study. V.G. Pons, S.L. Denlinger, B.J. Guglielmo, J. Octavio, J. Flaherty, C.B. Wilson. *Neurosurg.* **33**: 416 (1993).

35. Nosocomial Funguria: Resultant Morbidity and Therapeutic Intervention. A. Wong-Beringer, R.A. Jacobs, B.J. Guglielmo. *Clin. Infect. Dis.* **17**: 1066-7 (1993).

36. Management of Funguria. B.J. Guglielmo, M.L. Stoller, R.A. Jacobs. *Intern. J. Antimicrob. Agents* **3**: 10-18 (1994).

37. The New Macrolides: Azithromycin and Clarithromycin. M. Kanatani, B.J. Guglielmo. *West. J. Med.* **160**: 31-37 (1994).

38. Immune Globulin Therapy in Allogeneic Bone Marrow Transplant: A Critical Review. B.J. Guglielmo, A. Wong-Beringer, C. A. Linker. *Bone Marr. Trans.* **13**: 499-510 (1994).

**39**. Systemic Absorption of Oral Fluconazole After Gastrointestinal Resection. L. A. Joe, R.A. Jacobs, B.J. Guglielmo. *J Antimicrob Chemother* **33**: 1070 (1994).

40. Penetration of Fluconazole into Abscess Fluid. K.A. Kostiuk, V.G. Pons, B.J. Guglielmo. *J Antimicrob Chemother* **34**: 603-604 (1994).

41. Unit Dose Preparation of Colony Stimulating Factors: Determination of Sterility. R.F. Singh, R.L. Corelli, B.J. Guglielmo. *Am J Hosp Pharm* **51**: 2811-2812 (1994).

42. Influence of Timing of Antibiotic Administration on Tissue Concentration During Surgery. A. Wong-Beringer, R.L Corelli, T.R. Shrock, B.J. Guglielmo. *Am J Surg* **56**: 379-381 (1995).

**43**. Practical Strategies for the Appropriate Use of Antimicrobials. B.J. Guglielmo. *Pharmacy World & Science* **17**: 96-102 (1995).

44. Aerosolization of Imipenem/cilastatin Prevents Pseudomonas-induced lung injury. S. Hashimoto, E. Wolfe, B. Guglielmo, R. Shanks, J. Sundelof, J. Pittet, E. Thomas, J. Weiner-Kronish *J Antimicrob Chemotherapy* **38:** 809-18 (1996)

45. Comparison of the Pharmacokinetics of Once-daily Versus Thrice-daily Tobramycin in Cystic Fibrosis Patients. B.J. Guglielmo, L. A. Quan, M.S. Stulbarg. *J Antimicrob Chemother* **37**: 1040-1042 (1996).

46. Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci. A.D. Luber, R.A. Jacobs, M. Jordan, B.J. Guglielmo. *J Infect Dis* **173**: 1292-1293 (1996).

47. Impact of dosage-monitoring system on frequency of seizures associated with imipenemcilastatin. B.J. Guglielmo, R.A. Jacobs. *Am J Health Syst Pharm* **53**: 2097-2098 (1996)

48. Hypothermia following the intravenous administration of amphotericin B. T Barlows, A.D. Luber, R. A. Jacobs, B.J. Guglielmo. *Clin Infect Dis* **23**: 1187-8 (1996).

49. Aerosolized amphotericin B in prophylaxis of pulmonary aspergillosis. C Tsourounis, B.J. Guglielmo *Ann Pharmacother* **30**: 1175-1176 (1996)

50. The evolution of an antimicrobial review system at a university teaching hospital. A. D. Luber, R. C. Corelli, J. F. Flaherty, K.A. Kostiuk, M.D. Robinson, B.J. Guglielmo. *J Infect Dis Pharmacother* **2:** 65-90 (1996).

51. Pharmacokinetics and pharmacodynamics of ceftizoxime in abscess fluid. B. J. Guglielmo, K. A. Kostiuk, V. G. Pons. *J Antimicrob Chemother* **39**: 437-8 (1997).

52. (Reply) Hypothermia following the intravenous administration of amphotericin B. B.J. Guglielmo, A.D. Luber, R.A. Jacobs. *Clin Infect Dis* **25**: 757 (1997).

53. Lipid formulations of amphotericin B: clinical efficacy and toxicities. A Wong-Beringer, R.A. Jacobs, B.J. Guglielmo. *Clin Infect Dis* **27**: 603-18 (1998).

54. Risk factors for amphotericin B-induced nephrotoxicity. A.D. Luber, L. Maa, M. Lam, B.J. Guglielmo. *J Antimicrob Chemother* **43**: 267-71(1999)

55. Prevention of adverse antimicrobial events in hospitalized patients using an antimicrobial review program. B.J. Guglielmo, R.C. Corelli, J.F. Flaherty, A.D. Luber, R.A.Jacobs. *West J Med* 1999 **171**: 159-62.

56. ASHP Therapeutic Guidelines for Nonsurgical Antimicrobial Prophylaxis. Expert Panel: Bosso JA, Ebert SC, Flaherty JF, Guglielmo BJ, Nicolau DP, Plaisance K, DiPiro JT, Danziger LH. *Am J Health Syst Pharm* 1999; **56**: 1201-50.

57. ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. Expert Panel: Bosso JA, Ebert SC, Flaherty JF, Guglielmo BJ, Nicolau DP, Plaisance K, DiPiro JT, Danziger LH. *Am J Health Syst Pharm* 1999; **56**: 1839-88.

58. Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model. E.J. Ernst, S. Hashimoto, J. Guglielmo, T. Sawa, J-F Pittet, H. Kropp, J.J. Jackson, J.P. Wiener-Kronish. *Antimicrob Agents Chemother* 1999; **43**: 2389-94.

59. Ceftriaxone treatment of staphylococcal osteomyelitis. B. J. Guglielmo, A.D. Luber, D. Paletta, R.A. Jacobs. *Clin Infect Dis* 2000; **30:** 205-7.

60. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: A survey of non-teaching US community hospitals. V. Dudas, A. Hopefl, R. Jacobs, B. J. Guglielmo. *Ann Pharmacother* 2000; **34**: 446-51.

61. Impact of a restriction policy for intravenous fluconazole on patient outcomes. J.S. Burkiewicz, K.A. Kostiuk, R.A.Jacobs, B.J. Guglielmo. *Ann Pharmacother* 2001; **35**: 9-13.

62. Restricted access to automated dispensing machines for surgical prophylaxis. K. Botwin, J. Chan, R. Jacobs, B.J. Guglielmo. *Am J Health Syst Pharm* 2001; **58**: 797-9.

63. Antimicrobial therapy of gram-negative bacteremia at two university-affiliated medical centers. L. R. Graff, K. K. Franklin, L. Witt, N. Cohen, R. A. Jacobs, L. Tompkins, B. J. Guglielmo. *Am J Med* 2002; **112**: 204-211.

64. Characteristics of antimicrobial overrides associated with automated dispensing machines. E. Oren, L.P. Griffiths, B.J.Guglielmo. *Am J Health Syst Pharm* 2002; **59:** 1445-1448.

65. Pharmacy-based intervention to reduce antibiotic use for acute bronchitis. D.E. Hickman, M.R. Stebbins, J.R. Hanak, B.J. Guglielmo. *Ann Pharmacother* 2003; **37**: 187-81.

66. Impact of emerging technologies on medication errors and adverse drug events. E. Oren, E. Shaffer, B.J. Guglielmo *Am J Health Syst Pharm* 2003; **60:** 1447-58.

67. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. D.D. Phan, P. Chin-Hong, E.T. Lin, P. Anderle, W. Sadee, B.J Guglielmo. *Antimicrob Agents Chemother* 2003; **47:** 2351-53.

68. Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B. A.N. Bower, H.M. Tang, B.J. Guglielmo. *Am J Health Syst Pharm* 2004; **61**: 915-920.

69. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. K.M. Killgore, K.L. March, B.J. Guglielmo. *Ann Pharmacother* 2004; **38:** 1148-52.

70. Pharmacokinetics of valacyclovir. C. MacDougall, B.J. Guglielmo. *J Antimicrob Chemother* 2004; **53**: 899-901.

71. Pharmacokinetics of quinacrine in the treatment of prion disease. L Yung, Y. Huang, P. Lessard, G. Legname, E.T. Lin, M. Baldwin, S.B. Prusiner, C. Ryou, B.J. Guglielmo. *BMC Infectious Diseases* 2004; **4**: 53.

72. Culture and allergy history do not influence fluoroquinolone use in the treatment of moderate-to-severe community acquired pneumonia. N.N. Chang, C.K Murray, P.M. Houck, D.W. Bratzler, C. Greenway, B.J. Guglielmo. *Pharmacotherapy* 2005; **25**: 59-66.

73. Antimicrobial drug prescribing for pneumonia in primary care. C. MacDougall, B.J. Guglielmo, J Maselli, R. Gonzales. *Emerg Infect Dis* 2005; **11**: 380-384..

74. Continuous quality improvement with vancomycin prescribing: impact upon appropriateness of use and prevalence of vancomycin resistant enterococci. B. J. Guglielmo, V. Dudas, I. Maewal, R. Young, A. Hilts, M. Villmann, L. Gibbs, M. Gropper, R. Jacobs. *Joint Commission Journal Health and Safety* 2005; **31:** 469-475.

75. Impact of a piperacillin-tazobactam shortage upon antimicrobial prescribing and the rate of vancomycin-resistant enterococcus and Clostridium difficile infection. M. Mendez, L. Gibbs, R. A. Jacobs, C. E. McCulloch, L. Winston, B. J. Guglielmo. *Pharmacotherapy* 2006; **26:** 61-7.

76. In vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: *Balamuthia mandrillaris, Acanthamoeba* spp., and *Naegleria fowleri*. F.L. Schuster, B. J. Guglielmo, G.S.Visvesvara. *Journal of Eukaryotic Microbiology* 2006; **53**(2):121-6.

77. Dose-response effect of tetracyclines on cerebral matrix mealloproteinase-9 after vascular endothelial growth factor hyperstimulation. Lee, Chanhung Z., Yao, Jianhua S., Huang, Yong, Zhai, Wenwu, Liu, Weizhong, Guglielmo, B. Joseph, Lin, Emil, Yang, Guo-Yuan, Young, William L. *Journal of Cerebral Blood Flow & Metabolism* 2006; **26**:1157-64

78. Quinacrine is Mainly Metabolized to Mono-Desethyl Quinacrine by CYP3A4/5 and Pglycoprotein Limits its Brain Accumulation . Yong Huang, Hideaki Okochi, Barnaby C. H. May,Giuseppe Legname, Stanley B. Prusiner, Leslie Z. Benet, B. Joseph Guglielmo, Emil T. Lin. *Drug Metabolism and Disposition* 2006; **34**(7):1136-44

79. Pharmacological Advances in the Treatment of Invasive Candidiasis. Daniel Deck, B. Joseph Guglielmo. *Expert Rev Infect Dis* 2006; **4:** 137-49.

80. *In vivo* effect of I'm-Yunity on hepatic cytochrome P450 3A4, Nicandro JP, Tsourounis C, Frassetto L, Guglielmo BJ, *J Herb Pharmacother* 2007;7(1):39-56.

81. Antifungal prophylaxis in chemotherapy-associated neutropenia: comparative costs and patient outcomes. Reidel, A, Yuen C, Inciardi J, Chau LS, Martin, T, Guglielmo BJ. *BMC Infectious Diseases* 2007 Jul 2;7:70

82. Staggered sensitivity results. Guglielmo BJ. AHRQ Web M&M Case & Commentary. March 2007.

83. Clinical laboratory needs for pharmacogenomic testing. Wu, AHB, Guglielmo J, Hamill T, Haller C. Electronic letter. *Ann Intern Med.* February 1, 2007.

84. Discordance Between Ambulatory Care Clinic and Community Pharmacy Medication Databases for HIV-positive Patients. Robinson C, Cocohoba J, MacDougall C, John M, Guglielmo BJ. *J Am Pharm Assoc* 2007 Sep-Oct;47(5):613-5

85. Diagnosis and treatment of extended-spectrum and ampC beta-lactamase-producing organisms. Yang K, Guglielmo BJ. *Ann Pharmacother* 2007; **41:**1427-35

86. Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: Impact of protein binding? Schwartz BS, Ngo, PD, Guglielmo B J. *Ann Pharmacother* 2008; **42:** 289-90

87. Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T, Lawton MT, Guglielmo BJ, McCulloch CE, Young WL. *Cerebrovasc Dis* 2008; **25:** 157-163.

88. Antimicrobial stewardship programs. Interventions and associated outcomes. Patel, D, Lawton W, Guglielmo BJ. *Expert Review of Anti-infective Therapy* 2008; **6:** 209-22.

89. *Moringa oleifera* leaf and root extracts inhibit 6b-hydroxylation of testosterone by CYP3A4. Monera TG, Maponga CC, Benet LZ, Guglielmo J. *J Infect Dev Countr* 2008; **2**(5):379-83.

90. Five years later: re-examining the financial burden of boosting with Norvir. Marquez C, Guglielmo BJ, Klausner JD. *AIDS* 2008; **22**(17):2402-4.

91. Multi-drug resistant Pseudomonas aeruginosa ventilator-asociated pneumonia: the role of endotracheal aspirate surveillance cultures. Yang KYY, Zhuo H, Guglielmo BJ, Wiener-Kronish J. *Ann Pharmacother* 2009 Jan;**43**(1):28-35.

92. In vitro inhibitory effects on CYPs 1A2, 2C9, 2C19, 2D6 and 3A4 and on P-glucoprotein of Hyposix obtuse (African potato) and Dicuma anomola (chifumuro). Gwaza L, Wolfe AR, Benet LZ, Guglielmo BJ, Chagwedera TE, Maponga CC, Masimirembwa CM. *Afr J Pharmacy Pharmacol* 2009; **3**: 539-546.

93. Current recommended dosing of vancomycin for children with invasive MRSA infections is inadequate. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. *Ped Infect Dis J* 2009 May;**28**(5):398-402

94. Development of daptomycin-susceptible MRSA pneumonia during high-dose daptomycin therapy. Belkin-Kolpewicz Y, Schwartz, B, Guglielmo BJ. *Clin Infect Dis* 2009 **49**(8):1286-7.

95. Training the next generation of research mentors: the University of California, San Francisco, Clinical & Translational Science Institute Mentor Development Program. Feldman MD, Huang L, Guglielmo BJ, Jordan R, Kahn J, Creasman JM, Wiener-Kronish JP, Lee KA, Tehrani A, Yaffe K, Brown JS. *ClinTransl Sci.* 2009 Jun 1;2(3):216-221.

96. Voriconazole is safe and effective as prophylaxis for early and late fungal infection following allogeneic hematopoietic stem cell transplantation. Martin T, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, O'Malley R, Hwang J, Linker C. Transpl Infect Dis. 2009 **12:** 45-50.

97. Possible Neuropsychiatric Reaction to High-dose Oseltamivir during Acute H1N1 Influenza A Infection. Nakamura K, Schwartz, B.S., Lindegårdh, Niklas, Keh, C, Guglielmo BJ. *Clin Infect Dis* 2010 **50:** E47-49.

98. Coverage of FDA medication boxed warnings in commonly used drug information resources. Cheng, CM, Guglielmo BJ, Maselli J, Auerbach, AD. *Arch Intern Med* 2010; **170:** 831-3

99. The FDA extended warning for intravenous haloperidol and torsades de pontes: how should institutions respond? Meyer-Massetti, C, Cheng CM, Sharpe BA, Meier C, Guglielmo BJ. *J Hosp Med* 2010 **5**(4): E8-16

100. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Frymoyer A, Coralic Z, Hersh A, Benet LZ, Guglielmo BJ. *Clin Ther* 2010; **32**(3): 534-42

101. Risk factors and risk adjustment for surgical site infections in pediatric cardiothoracic surgery patients. Sohn AH, Schwartz JM, Yang KY, Jarvis WR, Guglielmo BJ, Weintrub P.S. Am J Infect Control 2010 Nov; **38**(9):706-10.

102. A prescription for improved chronic disease management: have community pharmacists function at the top of their training. (Commentary) Guglielmo BJ. *Arch Intern Med* 2010; Oct 11;170(18):1646-7.

103. National estimates and predictors of prescription medication sample use in the United States, 1999-2005. MacDougall C, Udkow T, Guglielmo BJ, Vittinghoff E, Martin J. *J Am Pharm Assoc* 2010, Nov-Dec;**50**(6):677-685

104. Systematic review of medication safety assessment methods. Meyer-Massetti, C, Schwappach DLB, Paulsen L, Ide B, Meier CR, Guglielmo BJ. *Am J Health-Syst Pharm* 2011 Feb 1;**68**(3):227-40.

105. Prescription Drug Label Adverse Events: A Call for Prioritization. (Commentary) Cheng C, Guglielmo BJ. *Arch Intern Med* 2011; 171(10):946-7.

106. Meyer-Massetti C, Vaerini S, Rätz Bravo AE, Meier CR, Guglielmo BJ. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm. 2011 Oct; 33(5):806-14.

107. Guglielmo BJ, Edwards DJ, Franks AS, Naughton CA, Schonder KS, Stamm PL, Thornton P, Popovich NG. A critical appraisal of and recommendations for faculty development. Am J Pharm Educ. 2011 Aug 10; 75(6):122.

108. Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011 Sep; 31(9):871-6.

109. Cheng CM, Fu C, Guglielmo BJ, Auerbach AD. Boxed warning inconsistencies between drug information resources and the prescribing information. Am J Health Syst Pharm. 2011 Sep 1; 68(17):1626-31.

110. Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Swartling M, Gupta R, Dudas V, Guglielmo BJ. *Int J Clin Pharm* 2012; 34(2):282-5.

111. Improved antiretroviral refill adherence in HIV-focused community pharmacies. Cocohoba JM, Murphy P, Pietrandoni G, Guglielmo BJ. *J Am Pharm Assoc* 2012 (in press)

112. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. Murphy P, Cocohoba J, Tang A, Pietrandoni G, Hou J, Guglielmo BJ. *AIDS Patient Care STDS*. 2012; 6(9):526-31.

113. The colchicine debacle (Commentary). Guglielmo BJ. Arch Intern Med 2012 (in press)

## NON-PEER REVIEWED PUBLICATIONS AND OTHER CREATIVE ACTIVITIES:

1. Guidelines for the Addition of Phenytoin to IV Solutions. B.J. Guglielmo. *UCSF Pharm. Ther. Forum* **27**, No. 6, 3-4 (1979).

2. Evaluation of the Use of Corticosteroids. B.J. Guglielmo. Crit. Care Quart. 2, 37-42 (1980).

3. Betablockers: A Comparison. B.J. Guglielmo. *Pharm. Ther. Forum* **30**, 1-3 (1982).

4. Furosemide-Aminoglycoside Interaction. B.J. Guglielmo. *Drug Interact. Newslett.* **4**, 34-35 (1984).

5. The Calcium Channel Blockers. B.J. Guglielmo. Pharm. Ther. Forum 32, 9-11 (1984).

6. Treatment of Opportunistic Infection in Patients with the Acquired Immunodeficiency Syndrome. B.J. Guglielmo. *Highlights on Antineoplastic Drugs* **5**, 15-18 (1987).

7. Biotechnology Agents in Infectious Diseases. B.J. Guglielmo. *Pharmaguide to Hospital Medicine* **4**, 1-4 (1991).

8. Use of antimicrobial agents in patients with cardiovascular disease. B.J. Guglielmo. *J Cardiovasc Nurs* **13**: 23-30 (1999).

## **Books and Chapters**

1. *Handbook of Applied Therapeutics*. Edited by L.Y. Young, M.A. Koda-Kimble, B.J. Guglielmo, and W. Kradjan. Vancouver, Washington: Applied Therapeutics, Inc., 1989.

2. Assistant Editor, *Applied Therapeutics*. *The Clinical Use of Drugs*. Edited by M.A. Koda-Kimble, L.Y. Young. Applied Therapeutics, Inc. Vancouver, Washington, 1992.

3. *Handbook of Applied Therapeutics*. Edited by M.A. Koda-Kimble, L.Y.Young, W. Kradjan, B.J. Guglielmo. Applied Therapeutics, Inc. Vancouver, Washington (1992).

4. Associate Editor, *Applied Therapeutics. The Clinical Use of Drugs.* Edited by L.Y. Young, M.A. Koda-Kimble. Applied Therapeutics, Inc. Vancouver, Washington, 1995.

5. *Handbook of Applied Therapeutics*. Edited by L.Y. Young, M.A. Koda-Kimble, B. Joseph Guglielmo, W.A. Kradjan. Vancouver, Washington: Applied Therapeutics, Inc. 1996.

6. Associate Editor, *Applied Therapeutics. The Clinical Use of Drugs*. Edited by M.A. Koda-Kimble, L.Y.Young. Lippincott, Williams & Wilkins, Baltimore, Maryland, 2001.

7. *Handbook of Applied Therapeutics*. Edited by M.A. Koda-Kimble, L.Y.Young, W. A. Kradjan, B. J. Guglielmo. Lippincott, Williams & Wilkins, Baltimore, Maryland, 2002.

8. Associate Editor, *Applied Therapeutics. The Clinical Use of Drugs*. Edited by M.A. Koda-Kimble, L.Y.Young, W.A. Kradjan, B.J. Guglielmo, R.C. Corelli, B. K. Alldredge. Lippincott, Williams & Wilkins, Baltimore, Maryland, 2004. 9. Editor, *Applied Therapeutics. The Clinical Use of Drugs*. Edited by M.A. Koda-Kimble, L.Y.Young, B. K. Alldredge, R.C. Corelli, B.J. Guglielmo, W.A. Kradjan, B.R. Williams. Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia, Pennsylvania 2008.

10. Editor, *Applied Therapeutics. The Clinical Use of Drugs*. Edited by B. K. Alldredge, R.C. Corelli, ME Ernst, B.J. Guglielmo, PA Jacobson, W.A. Kradjan, B.R. Williams. Wolters Kluwer/ Lippincott, Williams & Wilkins, Philadelphia, Pennsylvania 2013.

11. Articles and Chapters in books

12. Infectious Diseases. L.Y. Young, B.S. Katcher, and M.A. Koda-Kimble. In *Applied Therapeutics for Clinical Pharmacists, 3rd Ed,* pp. 663-870. Edited by L.Y. Young, B.S. Katcher, and M.A. Koda-Kimble. Editor and Coordinator B.J. Guglielmo. San Francisco: Applied Therapeutics, Inc., 1983.

13. Endocarditis. B.J. Guglielmo. In *Applied Therapeutics for Clinical Pharmacists, 3rd Ed*, pp. 663-678. Edited by L.Y. Young, B.S. Katcher and M.A. Koda-Kimble. San Francisco: Applied Therapeutics, Inc., 1983.

14. Surgical Antibiotic Prophylaxis. B.J. Guglielmo. In *Applied Therapeutics for Clinical Pharmacists, 3rd Ed,* pp. 725-748. Edited by L.Y. Young, B.S. Katcher and M.A. Koda-Kimble. San Francisco: Applied Therapeutics, Inc., 1983.

15. Antimicrobial Prophylaxis in Surgical Procedures. B.J. Guglielmo and G.F. Brooks. In *Medical Microbiology, Vol. 5.* Edited by J. Jeljaszewicz and C.S.F. Easmon. London: Academic Press, 1986.

16. Editorial Assistant for Infectious Diseases. B.J. Guglielmo. In *Applied Therapeutics, The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Vancouver, Washington: Applied Therapeutics, Inc., 1988.

17. Principles of Antimicrobial Therapy. B.J. Guglielmo. In *Applied Therapeutics, The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Vancouver, Washington: Applied Therapeutics, Inc., 1988.

18. Surgical Antibiotic Prophylaxis. B.J. Guglielmo. In *Applied Therapeutics, The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Vancouver, Washington: Applied Therapeutics, Inc., 1988.

19. Surgical Infection and Antibiotic Prophylaxis. B.J. Guglielmo. In *Clinical Pharmacy and Therapeutics*. Edited by E.T. Herfindal, R. Gourley, and L.L. Hart. Baltimore, Maryland: Williams & Wilkins, 1988.

20. Principles of Antimicrobial Therapy. BJ Guglielmo. In *Applied Therapeutics. The Clinical Use of Drugs*. Edited by MA Koda-Kimble and LY Young. Vancouver, Washington: Applied Therapeutics, Inc., 1992.

21. Surgical Antibiotic Prophylaxis. B.J. Guglielmo. In *Applied Therapeutics. The Clinical Use of Drugs*. Edited by M.A. Koda-Kimble and LY Young. Vancouver, Washington: Applied Therapeutics, Inc., 1992.

22. Pharmacotherapy. B.J. Guglielmo and M. Glick. In *Current Diagnosis and Treatment in Critical Care*. Edited by F.S. Bongard and D.Y. Sue. Appleton-Lange 1994.

23. Pharmacology. B.J. Guglielmo. In *Surgical Critical Care*. Edited by J.A. Moylan. Mosby-Year Book Inc. 1994.

24. Principles of Antimicrobial Therapy. B. J. Guglielmo. *In Applied Therapeutics. The Clinical Use of Drugs.* Edited by L.Y. Young and M.A. Koda-Kimble. Vancouver, Washington: Applied Therapeutics, Inc., 1995.

25. Pharmacotherapy. B.J. Guglielmo and M.Glick. In *Current Diagnosis and Treatment in Critical Care*. Edited by F.S. Bongard and D.Y. Sue. Appleton-Lange 1995.

26. Antimicrobial Prophylaxis for Surgical Procedures. L.L. Briceland, B.J. Guglielmo. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Vancouver, Washington: Applied Therapeutics, Inc., 1995.

27. Assessments of Therapy and Pharmaceutical Care. L.L. Young, W.A. Kradjan, B. Joseph Guglielmo, M.A. Koda-Kimble. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Vancouver, Washington: Applied Therapeutics, Inc., 1995.

28. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. Norwalk, Connecticut: Appleton & Lange, 1997.

29. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. Norwalk, Connecticut: Appleton & Lange, 1998.

30. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. Norwalk, Connecticut: Appleton & Lange, 1999.

31. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: Mcgraw-Hill, 2000.

32. Assessments of Therapy and Pharmaceutical Care. L.L. Young, W.A. Kradjan, B. Joseph Guglielmo, M.A. Koda-Kimble. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Baltimore, MD. Lippincott, Williams & Wilkins, 2001

**33**. Principles of Antimicrobial Therapy. B.J Guglielmo. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Baltimore, MD. Lippincott, Williams & Wilkins, 2001

34. Antimicrobial Prophylaxis for Surgical Procedures. B.J. Guglielmo, L.L. Briceland. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble. Baltimore, MD. Lippincott, Williams & Wilkins, 2001

35. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2001.

36. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2002.

37. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2003.

38. Treatment of Serious Pseudomonas aeruginosa infections. P. Voirol, B. J. Guglielmo. In *Severe Infections Caused by Pseudomonas aeruginosa*. Edited by Alan R. Hauser, Jordi Rello. Boston: Kluwer Academic Publishers, 2003.

**39**. Assessments of Therapy and Pharmaceutical Care. L.L. Young, W.A. Kradjan, B. Joseph Guglielmo, M.A. Koda-Kimble, R.C. Corelli, B.K. Alldredge. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble, et,al. Baltimore, MD. Lippincott, Williams & Wilkins, 2004

40. Principles of Antimicrobial Therapy. B.J Guglielmo. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble, et al. Baltimore, MD. Lippincott, Williams & Wilkins, 2004

41. Antimicrobial Prophylaxis for Surgical Procedures. D. Thirion, B.J. Guglielmo. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble, et al. Baltimore, MD. Lippincott, Williams & Wilkins, 2004

42. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2004.

43. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2005.

44. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2006.

45. Principles in Antimicrobial Therapy. R.A. Jacobs, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2007.

46. Overview of Antibiotics. Conan MacDougall, B. J. Guglielmo. *In Emergency Management of Infectious Diseases*. Edited by Rachel Chin. New York, New York: Cambridge University Press, 2008.

47. Principles of Antimicrobial Therapy. B.J Guglielmo. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble, et al. Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia, Pennsylvania 2008.

48. Antimicrobial Prophylaxis for Surgical Procedures. D. Thirion, B.J. Guglielmo. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by L.Y. Young and M.A. Koda-Kimble, et al. Wolters Kluwer/Lippincott, Williams & Wilkins, Philadelphia, Pennsylvania 2008.

49. Antimicrobial Overview. C MacDougall, BJ Guglielmo. *Emergency Management of Infectious Diseases*. Edited by R Chin. Cambridge, New York 2008.

50. Principles in the Treatment of Infectious Diseases. R.A. Jacobs, P. Chin-Hong. B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2008.

51. Principles in Antimicrobial Therapy. B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2008.

52. Principles in Infectious Diseases. R.A. Jacobs, P. Chin-Hong, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2009.

53. Principles in Antimicrobial Therapy. B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2009.

54. Principles in Infectious Diseases. P. Chin-Hong, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2010.

55. Principles in Antimicrobial Therapy. B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2010.

56. Antimicrobial Therapy. C. MacDougall, B.J. Guglielmo, J. Wiener-Kronish. In Anesthetic Pharmacology, 2<sup>nd</sup> edition, Elsevier, 2010.

57. Principles in Infectious Diseases. P. Chin-Hong, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2011.

58. Principles in Antimicrobial Therapy. B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2011.

59. Principles in Infectious Diseases. P. Chin-Hong, B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2012.

60. Principles in Antimicrobial Therapy. B.J. Guglielmo. In *Current Medical Diagnosis & Treatment*. Edited by Lawrence M. Tierney, Jr., Stephen J. McPhee, & Maxine Papadakis. New York, New York: McGraw-Hill, 2012.

61. Principles of Antimicrobial Therapy. B.J Guglielmo. In *Applied Therapeutics: The Clinical Use of Drugs*. Edited by BK Alldredge, et al. Wolters Kluwer/ Lippincott, Williams & Wilkins, Philadelphia, Pennsylvania 2013.

# ABSTRACTS

1. Wong R, Guglielmo BJ, Winter ME. Intramediastinal absorption of kanamycin. California Society of Hospital Pharmacists Seminar '84. San Francisco, California (September, 1984)

2. Ignoffo RJ, Kayser SR, Davis LJ, Koo PJ, Guglielmo BJ. Implementation of a protocol under SB502. California Society of Hospital Pharmacists Seminar '84. San Francisco, California (September, 1984)

3. Barriere SL, Guglielmo BJ, Flaherty JF, Deeter R, Fekety R, Gambertoglio JG. Comparison of mezlocillin and ticarcillin kinetics: Absence of dose-dependency with ticarcillin. Twenty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. Minneapolis, Minnesota (September, 1985)

4. Salazar T, Guglielmo BJ, Chun L. Altered pharmacokinetics of antibiotics during surgery. California Society of Hospital Pharmacists Seminar '85. Long Beach, California (October, 1985)

5. Wong RJ, Stevens MB, Guglielmo BJ, Winter ME, Hoffman JIE. Systemic absorption of kanamycin following mediastinal irrigation in dogs. American College of Chest Physicians. New Orleans, Louisiana (October, 1985)

6. Brodowy B, Guglielmo BJ, Herfindal ET. Impact of a restricted antimicrobial culture and sensitivity reporting system on prescribing. American Society of Hospital Pharmacists Midwinter Clinical Meeting. New Orleans, Louisiana (December, 1985)

7. Lim D, Guglielmo BJ. Third-generation cephalosporin usage at a large university hospital: utility as monotherapy? American Society of Hospital Pharmacists Midyear Clinical Meeting. Las Vegas, Nevada (December, 1986)

8. Rodondi K, Guglielmo BJ. Development of an ongoing vancomycin audit using a restricted antimicrobial reporting system. American Society of Hospital Pharmacists Midyear Clinical Meeting. Las Vegas, Nevada (December, 1986)

9. McCauley DL, Winter ME, Guglielmo BJ, Cohen N. Impact of a pharmacist on therapeutic drug level monitoring in an intensive care unit. American Society of Hospital Pharmacist Midyear Clinical Meeting. Atlanta, Georgia (December, 1987)

10. Lowe AG, Guglielmo BJ, Winter ME.ï¿<sup>1</sup>/<sub>2</sub> Improving clearance estimates for the aminoglycoside antibiotics. American Society of Hospital Pharmacists Midyear Clinical Meeting. Atlanta, Georgia (December, 1987)

11. Guglielmo BJ, Duroux MJH, Lam YWF, Gambertoglio JG. Effect of protein binding on serum bactericidal activity of ceftazidime and cefoperazone. American Society for Clinical Pharmacology and Therapeutics Annual Meeting. San Diego, California (March, 1988)

12. Tam J, Guglielmo BJ, Hollander H, Hassanzadeh M. Bayesian estimation of the pharmacokinetic parameters of chronic zidovudine (ZDV)in HIV-infected patients. V International Conference on AIDS. Montreal, Canada (June, 1989)

13. Guglielmo BJ, Tam J, Hollander H, Gambertoglio JG, Hassanzadeh M. Correlation of pharmacokinetic parameters and severity of neutropenia from zidovudine (ZDV)therapy. International Conference on Antimicrobial Agents and Chemotherapy. Houston, Texas (September, 1989)

14. Chin MK, Kishi DT, Guglielmo BJ. Ribavirin:� Appropriateness of use and environmental effects. American Society of Hospital Pharmacists Midyear Clinical Meeting. Atlanta, Georgia (December, 1989)

15. Guglielmo BJ, Flaherty JF, Octavio J, Wilson C, Pons VG. Comparison of ceftizoxime and vancomycin in patients undergoing clean neurosurgical procedures. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia (October, 1990)

16. Corelli R, Guglielmo BJ. Use of an antimicrobial order sheet in a university teaching hospital. American Society of Hospital Pharmacists Annual Meeting. San Diego, California (June, 1991)

17. Corelli RL, Haas J, Guglielmo BJ. Prior treatment with third-generation cephalosporin is associated with subsequent isolation of third-generation cephalosporin-resistant gram-negative rods. International Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois (September, 1991)

18. Oliva SL, Guglielmo BJ. Lack of cost difference between ceftazidime monotherapy and piperacillin and tobramycin as empiric drug therapy in the febrile, neutropenic patient. American Society of Hospital Pharmacists Midyear Clinical Meeting. New Orleans, Louisiana (December, 1991)

19. Corelli RL, Guglielmo BJ, Carroll DJ, Aweeka FT, Gambertoglio JG, Winter ME. Development of a hospital-wide adult antimicrobial dosing guideline. American Society of Hospital Pharmacists Midyear Clinical Meeting. New Orleans, Louisiana (December, 1991)

20. Wong-Beringer A, Guglielmo BJ. Nosocomial funguria: resultant morbidity and therapeutic intervention. American Society of Hospital Pharmacists Midyear Clinical Meeting. New Orleans, Louisiana (December, 1991)

21. Pang TA, Corelli R, Guglielmo BJ. Patient outcomes associated with the use of G-CSF in bone marrow transplantation. American Society of Hospital Pharmacists Midyear Clinical Meeting. Orlando, Florida (December, 1992)

22. Wong-Beringer A, Guglielmo BJ, Corelli RL. Influence of timing of antibiotic administration on tissue concentrations. American Society of Hospital Pharmacists Midyear Clinical Meeting. Orlando, Florida (December, 1992)

23. Lauderman ML, Guglielmo BJ, Corelli RL. Drug utilization evaluation (DUE) of the colonystimulating factors (CSF's) American Society of Hospital Pharmacists Midyear Clinical Meeting. Orlando, Florida (December, 1992)

24. Quan DJ, Guglielmo BJ. Correlation of antimicrobial use with susceptibility patterns. American Society of Hospital Pharmacists Midyear Clinical Meeting. Atlanta, Georgia (December, 1993)

25. Guglielmo BJ, Kanatani MS, Matthay MA. Adequate antimicrobial therapy does not decrease the incidence of sepsis-associated acute respiratory distress syndrome (ARDS) American Lung Association/American Thoracic Society International Conference. Boston, Massachusetts (May, 1994)

26. Hashimoto S, Wolfe E, Guglielmo B, Shanks R, Sundelof J, Pittet J, Wiener-Kronish J. Aerosolization of imipenem/cilastatin prevents pseudomonas-induced lung injury. Cystic Fibrosis Foundation. Eighth Annual North American Conference. Orlando, Florida (October, 1994)

27. Robinson M, Guglielmo BJ. Correlation of antimicrobial usage with the incidence of C. difficile colitis. American College of Clinical Pharmacy Winter Meeting, Orlando, Florida (February, 1995)

28. Jones J, Corelli R, Guglielmo BJ. Interventions by staff pharmacists participating in a antimicrobial review program. American Pharmaceutical Association Annual Meeting, Memphis (March, 1996)

29. Guglielmo BJ, Robinson M. Pharmacokinetics and pharmacodynamics of oral itraconazole in immunocompromised patients. 7th International Congress for Infectious Diseases, Hong Kong (June, 1996)

30. Lucich JL, Kostiuk K, Guglielmo BJ. Epidemiology of third-generation cephalosporinresistant gram-negative bacteremia in intensive care unit patients. 7th International Congress for Infectious Diseases, Hong Kong (June, 1996) 31. Guglielmo BJ, Corelli RL, Flaherty JF, Kostiuk KA, Luber AD, Robinson MD, Jacobs RA. An antimicrobial monitoring system improves therapeutic efficacy and reduces toxicity in hospitalized patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans (September, 1996)

32. Kostiuk KA, Stoller ML, Guglielmo BJ, Jacobs RA, Gentle DL. Prospective randomized clinical trial of amphotericin B bladder irrigations in patients with funguria. 1997 Annual Meeting of the American Urological Association, New Orleans (April, 1997)

33. Gericke K, Guglielmo BJ. The impact of changes in human immunodeficiency virus therapy on prescription medication costs for a physician group practice. Spring Practice and Research Forum of the American College of Clinical Pharmacy, Panama City (April, 1997)

34. Barnes DE, Bero L, Fleshman R, Guglielmo J, Kishi D, Reed D. Medication use among residents of Marin County, CA aged 55 and older. Annual Scientific Meeting Program of the Gerontological Society of America. Cincinnati (November, 1997)

35. Guglielmo BJ, Dudas V, Jacobs RJ. Impact of an Automatic 72 hour stop policy for vancomyin on prescribing patterns. 35th Annual Meeting of the Infectious Diseases Society of America. San Francisco (September, 1997)

36. Guglielmo BJ, Dudas V, Hopefl A. Treatment outcomes associated with community-acquired pneumonia in US hospitals: a 3,000 patient survey. 37th Interscience Conference on Antimicrobial Chemotherapy, Toronto (September, 1997)

**37**. Guglielmo BJ, Maa L, Luber AD, Lam M. Risk factors for amphotericin B-induced nephrotoxicity. 37th Interscience Conference on Antimicrobial Chemotherapy, Toronto (September, 1997)

**38**. Hopefl A, Dudas V, Guglielmo BJ. Oral antimicrobial discharge therapy in patients admitted with community-acquired pneumonia to nonteaching hospitals: A national survey.1997)

39. Annual Meeting American College of Clinical Pharmacy. Phoenix, AZ (November, 1997)

40. Luber AD, Gassaway-Kilar J, Corelli RL, Guglielmo BJ, Koda-Kimble MA. A case-based, interactive anti-infective computer program which mimics pharmacist's daily activities. Annual Meeting of the American Association of Colleges of Pharmacy, Snowmass, CO (July, 1998)

41. Guglielmo BJ, Paletta D, Luber AD, Jacobs RA. Ceftriaxone is effective therapy in the treatment of S. aureus osteomyelitis. 36<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Denver, CO (November, 1998)

42. Hilts AE, Jones DN, Witt LG, Brooks G, Cohen H, Jacobs RA, Rizk N, Tompkins L, York M, Guglielmo BJ. Impact of inappropriately drawn blood cultures on vancomycin prescribing. 36<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Denver, CO (November, 1998)

43. Graff LR, Franklin K, Witt L, Brook G, Cohen H, Jacobs RA, Rizk N, Tompkins L, York M, Guglielmo BJ. Antimicrobial therapy and outcomes associated with gram negative bacteremia at

two university medical centers. 36<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Denver, CO (November, 1998)

44. Graff LR, Dudas V, Hilts A, Kostiuk K. Guglielmo BJ. Pharmacist-managed investigational drug treatment of vancomycin resistant enterococcal infection. American College of Clinical Pharmacy. Orlando (April, 1999)

45. Gasaway-Kilar J, Luber AD, Corelli RL, Guglielmo BJ, Koda-Kimble MA. A case-based, interactive computer program improves pharmacists' knowledge in antimicrobial chemotherapy. American College of Clinical Pharmacy. Kansas City (October, 1999)

46. Dudas VJ, Hopefl A, Jacobs R, Guglielmo BJ.ï¿<sup>1</sup>/<sub>2</sub> Treatment outcomes with initial oral and intravenous antibiotic therapy for community-acquired pneumonia. 37<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA (November, 1999)

47. Yang KY, Yuen CW, Jacobs RA, Linker CA, Ries CA, Guglielmo BJ. Antibacterial coverage can be safely narrowed in febrile neutropenic patients with negative cultures. 37<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA (November, 1999)

48. Guglielmo BJ, Kostiuk K, Dudas V, Graff L, Jacobs R. Evolution of a lipid-based amphotericin B policy and impact upon patient outcomes.� 28<sup>th</sup> European Symposium on Clinical Pharmacy. Berlin, Germany (October, 1999)

49. Dudas V, Hopefl A, Guglielmo BJ. Macrolide Utilization in the Treatment of Communityacquired Pneumonia (CAP)in US Hospitals. International Conference on the Macrolides, Azalides, Streptogramins,Ketolides and Oxazolidinones, Seville, Spain (January, 2000)

50. Botwin K, Chan J, Jacobs R, Guglielmo BJ. Impact of a 24 hour stop and restricted access to automated dispensing machines upon duration of surgical antibiotic prophylaxis. 2000 Spring Practice and Research Forum of the American College of Clinical Pharmacy, Monterey, California (April, 2000)

51. Luber A, Guglielmo BJ. Decision support systems via the use of interactive computer programs - Experience with an HIV treatment algorithm. Second Annual Meeting on Pharmaceutical Outcomes Research, Seattle, Washington (May, 2000)

52. Tokumaru S, Dudas V, Guglielmo BJ. A blood culture sampling protocol does not reduce the incidence of inappropriately drawn blood cultures and� subsequent vancomycin use. 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA (September, 2000)

53. Hickman D, Stebbins M, Hanak J, Huang J, Guglielmo BJ. An outpatient-based intervention program reduces antibacterial use in the treatment of acute bronchitis. 40<sup>th</sup> Interscience Conference on Antimicrobial Chemotherapy, Toronto, Canada (September, 2000)

54. Borland L, Guglielmo BJ. Patient outcomes associated with restricted use of lipid-based formulations of amphotericin B. 40<sup>th</sup> Interscience Conference on Antimicrobial Chemotherapy, Toronto, Canada (September, 2000)

55. Svete F, Dudas V, Jacobs R, Guglielmo BJ. Antimicrobial treatment of positive intravenous catheter tip cultures in nonbacteremic patients. 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA (October, 2001)

56. El-Ibiary S, Dudas V, Jacobs R, Guglielmo BJ. Antibiotic treatment of surgical drain cultures. 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA (October, 2001)

57. Oren E, Griffiths LP, Guglielmo BJ. Demographics of antimicrobial override associated with automated dispensing machines. American Society of Health Systems Pharmacists Midyear Clinical Meeting, New Orleans, LA (December, 2001)

58. Chang N. N., Murray C.K., Bratzler D.W., Houck P. M., Moore L., Shook C., Guglielmo B. J.. Fluoroquinolone use associated with pneumococcal pneumonia. 42<sup>nd</sup> Interscience Conference on Antimicrobial Chemotherapy, San Diego, CA (September, 2002)

59. Phan D., Chin-Hong P., Lin E., Sadee W., Guglielmo, B.J. Reduction in valaycyclovir bioavailability associated with a competitive inhibitor of hPEPT1. 42<sup>nd</sup> Interscience Conference on Antimicrobial Chemotherapy, San Diego, CA (September, 2002)

60. Thirion D., Jacobs R., Nadarajah R., Guglielmo, B.J. What is the utility of a rapid detection system in the antimicrobial treatment of S. aureus infection? 42<sup>nd</sup> Interscience Conference on Antimicrobial Chemotherapy, San Diego, CA (September, 2002)

61. Tam E, Yang K.Y., Jacobs R., Guglielmo B.J.Breakthrough fungal infections in neutropenic patients receiving prophylactic amphotericin B and colony stimulating factors. 40<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Chicago (October, 2002)

62. Tang H, Bower A, Guglielmo B.J. Caspofungin and lipid-based amphotericin:� appropriateness of use and patient outcomes. 40<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Chicago (October, 2002)

63. Yeh R.F., Jacobs R., Guglielmo B.J. Appropriateness of linezolid use and isolation of linezolid-resistant enterococci. 40<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Chicago (October, 2002)

64. Jancel T., Dudas V., Jacobs R., Guglielmo B.J. Evaluating the effectiveness of an intervention model for combination gram-negative antimicrobials in critically ill patients. 40<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Chicago (October, 2002)

65. Guglielmo B.J., Graff L., Linker C., Brooks GF, Jacobs R. Emergence of fluoroquinoloneresistant viridans streptococci associated with levofloxacin prophylaxis in neutropenic cancer patients. 40<sup>th</sup> Annual Meeting of the Infectious Diseases Society of America, Chicago (October, 2002)

66. Guglielmo BJ, Killgore K, March K. Risk factors for community ciprofloxacin-resistant E. coli urinary tract infection. 43<sup>rd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (September, 2003)

67. Guglielmo BJ, Yung L, Huang Y, Lin E, Lessard P. Drug treatment of prion disease: applicable pharmacokinetics of quinacrine. 43<sup>rd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (September, 2003)

68. Guglielmo BJ, Mendez MN, Gibbs L, Jacobs R, Winston L, Komp G, Banh N, Ngo S, Chinn M, Yen C. Reduced piperacillin/tazobactam availability is associated with decreased incidence of C. difficile colitis. 43<sup>rd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (September, 2003)

69. Guglielmo BJ, Chau LS, Inciardi J, Yuen C. Cost analysis of amphotericin-based therapy in neutropenic hematology/oncology patients. 43<sup>rd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (September, 2003)

70. Robinson C, Cocohoba J, Yang K, Guglielmo BJ. Lack of concordance between computerized medical records and community pharmacy databases in HIV positive patients. 42nd Annual Meeting of the Infectious Diseases Society of America, Boston (October, 2004)

71. MacDougall C, Guglielmo BJ, Maselli J, Gonzales R. Trends in outpatient antibiotic treatment of community acquired pneumonia (CAP)by primary care physicians. 44<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC (November, 2004)

72. MacDougall C, Mendez M, Dudas VJ, Gropper MA, Jacobs RA, Guglielmo BJ. Comparative demographics of patients approved or denied the use of APC. 44<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC (November, 2004)

73. Reidel, A, Chau LS, Inciardi J, Yuen C, Guglielmo BJ. Antifungal prophylaxis in chemotherapy-associated neutropenia: comparative costs and patient outcomes. 45<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans (September, 2005)

74. Rychlewski M. Ho C, Ramirez R, Seto AC, Guglielmo BJ. Microbiological outcomes associated with levofloxacin versus moxifloxacin prophylaxis in neutropenic hematology-oncology patients. 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco (September, 2006)

75. Yang K, Dudas V, Teelucksingh K, Jacobs R, Gropper M, Vittinghoff E. Lin F, Zhuo, Guglielmo BJ. Failure of practice guidelines toward the appropriate use of empirical antibiotics in the critical care setting. 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco (September, 2006)

76. Teelucksingh K, Yang K, Dudas V, MacDougall C, Guglielmo J. Impact of caspofungin restriction policy on appropriateness of use and the financial implications in a large tertiary hospital. 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco (September, 2006)

77. Gwaza L, Wolfe A, Benet LZ, Guglielmo J, Chagwedera T, Maponga C, Masimirembwa C. In vitro evaluation of inhibition of CYP3A4, CYP1A2, and p-glycoprotein by herbal extracts. 1st

African Conference on Drug Metabolism and Development . Johannesburg, South Africa (May, 2007)

78. Frymoyer A, Hersh A, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive MRSA infections is inadequate. 48<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC (September, 2008)

79. Frymoyer A, Hersh A, Guglielmo BJ. Hospital-Wide Change in Empiric Vancomycin Dosing and Associated Trough Concentration. Abstract #751342, to the 2010 Pediatric Academic Societies' Annual Meeting, Vancouver, BC, Canada (May, 2010)

80. Arora S, Gayle R, Guglielmo BJ. Appropriate use of in vitro susceptibility testing in the selection of antifungal therapy. American College Clinical Pharmacy Annual Meeting, Fort Lauderdale, FL (October)

# **RESEARCH PROGRAM**

My research program is centered upon the safe, effective use of antimicrobials as well as evidence-based medicine. With respect to the antimicrobial research platform, I evaluate the pharmacoepidemiology of antiinfectives and investigate programs intended to improve the use of these agents. As part of my research with antimicrobials, I additionally study the pharmacokinetics and drug and drug-herb interactions associated with these agents. Lastly, in my role as Department Chair and Director of the Medication Outcomes Center, my focus has broadened to the safe and effective use of pharmaceuticals, in general.